Combination Therapies for Treating Cancer

The combination of ficlatuzumab and cetuximab provides a promising treatment for HPV-negative HNSCC patients who have progressed through platinum and immunotherapy, enhancing survival rates and addressing the limitations of current therapies.

JP2024543108AInactive Publication Date: 2024-11-19AVEO PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024529907
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-11-18
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for head and neck squamous cell carcinoma (HNSCC), particularly in recurrent or metastatic cases, are limited and ineffective, with patients often experiencing poor prognosis and limited survival rates, and there are no standard therapies for those who fail platinum and anti-EGFR therapies.

Method used

A combination therapy using ficlatuzumab, an HGF inhibitor, and cetuximab, an EGFR inhibitor, specifically targeting HPV-negative HNSCC patients who have progressed through platinum and immunotherapy, to enhance treatment efficacy.

Benefits of technology

The combination therapy significantly improves progression-free and overall survival rates in HPV-negative HNSCC patients, offering a potential replacement for cetuximab as a standard of care in second-line or back-line therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543108000001_ABST
    Figure 2024543108000001_ABST
Patent Text Reader

Abstract

The present invention provides improved methods of treating a subject with cancer, such as head and neck squamous cell carcinoma (HNSCC). In one aspect, the present invention provides a method of treating cancer in a subject in need of treatment. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of an HGF inhibitor and an EGFR inhibitor. In some embodiments, recurrent or metastatic HNSCC is treated with a combination of ficlatuzumab and cetuximab.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The fields of the invention are medicine, oncology, tyrosine kinase inhibitors, EGFR receptor inhibitors and pharmaceuticals. [Background technology]

[0002] Head and neck squamous cell carcinoma (HNSCC) is a morbid and fatal cancer resulting from habitual exposure to tobacco and other carcinogens or human papillomavirus (HPV). Head and neck squamous cell carcinoma (HNSCC) is the most common cancer occurring in the upper aerodigestive tract. With an estimated 600,000 cases in 2012, HNSCC is the sixth most common cancer worldwide (Kamangar, F. et al., Journal of Clinical Oncology (2006) 24:2137-2150). Despite advances in multimodality therapy, 5-year overall survival (OS) is 40-50% and has only gradually increased in the past 20 years (Jemal, A. et al., CA Cancer J Clin. (2010) 60:277-300). Patients with recurrent or metastatic (R / M) HNSCC have a particularly poor prognosis, with a median overall survival of 6-10 months. Palliative management options are limited. For nearly 30 years, the basis of first-line chemotherapy for R / M HNSCC has been platinum-based antitumor agents (platins), such as cisplatin (Hong, WK, et al., Cancer (1983) 52:206-210), often combined with fluorouracil or taxane derivatives due to increased response rates (RR), despite the lack of evidence of superior survival compared with cisplatin monotherapy (Forastiere, AA, et al., J Clin Oncol. (1992) 10:1245-1251).

[0003] The ubiquitous expression of EGFR has prompted the development of EGFR inhibitors for the treatment of HNSCC (Rubin Grandis, J. et al., J Natl Cancer Inst. (1998) 90:824-832; Chung, CH et al., J Clin Oncol. (2006) 24:4170-4176). Cetuximab, an EGFR-directed monoclonal antibody, is the only FDA-approved targeted therapy to date for the treatment of HNSCC and improves survival when added to frontline platinum (Vermorken, JB et al., N Engl J Med. (2008) 359:1116-1127). Despite aberrant EGFR signaling in the majority of HNSCC cases, the modest clinical activity of cetuximab has been disappointing, and either primary or acquired resistance is by far the most common occurrence. Currently, there are no predictive molecular markers for resistance or sensitivity to anti-EGFR therapy in HNSCC, including EGFR gene copy number (Licitra, L. et al., Ann Oncol. (2011) 22:1078-1087).

[0004] While immunotherapeutic antibodies that block programmed death receptor 1 (PD-1) have recently gained FDA approval for patients with platinum-resistant HNSCC, the overall survival (OS) benefit appears to be limited to approximately 20% (Seiwert, TY et al., Lancet Oncol. (2016) 17:956-965; Ferris, RL et al., J Clin Oncol. (2016) 34). Currently, there is no standard therapy for patients who fail platinum, cetuximab, and anti-PD1 therapy, and all such patients die with a median survival of less than 6 months. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] WO2018 / 132476 [Non-patent literature]

[0006]

Non-patent document 1

Non-patent document 2

Non-patent document 3

Non-patent document 4

Non-patent document 5

Non-patent document 6

Non-patent document 7

Non-patent document 8

Non-patent document 9

Non-patent document 10

Non-patent document 11

Non-patent document 12

Non-patent document 13

Non-patent document 14

Non-patent document 15

Non-patent document 16

Non-patent document 17

Non-patent document 18

Non-patent document 19

Non-patent document 20

Non-patent document 21

Non-patent document 22

[1975] [Non-Patent Document 26] Remington's Pharmaceutical Sciences, 18th edition (Mack Publishing Company, 1990 [Non-Patent Document 27] Jordan et al., Am J Surg Pathol. (2012) 36(7):945~954 [Non-Patent Document 28] Bauman et al., Journal of Clinical Oncology 35, No. 15 Supplement (May 20, 2017), pp. 6038-6038. [Non-Patent Document 29] Bauman et al., Cancers (Basel). 2020;12(6):1537, published June 11, 2020, doi:10.3390 / cancers12061537 Summary of the Invention [Problem to be solved by the invention]

[0007] Thus, there is a need for additional treatment options for patients with HNSCC, including recurrent or metastatic HNSCC. [Means for solving the problem]

[0008] The present invention provides improved methods of treating subjects with cancer, such as head and neck squamous cell carcinoma (HNSCC).

[0009] In one aspect, the present invention provides a method for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in a subject. The method includes identifying a subject with recurrent or metastatic HNSCC that is human papillomavirus (HPV) negative, and administering to the subject an effective amount of cetuximab together with an effective amount of ficlatuzumab to treat the HPV-negative HNSCC. In some embodiments, if the subject has recurrent or metastatic HNSCC that is HPV positive, the subject is not treated. In some embodiments, the HNSCC has not been previously treated with cetuximab, i.e., the HNSCC is cetuximab treatment naive.

[0010] In some embodiments, the HPV status of HNSCC is determined by p16 immunohistochemistry. For example, if HNSCC is p16 negative, HNSCC is classified as HPV negative. For example, if HNSCC is primary oral, laryngeal, or hypopharyngeal HNSCC, HNSCC is classified as HPV negative. For example, if HNSCC is p16 positive, HNSCC is classified as HPV positive. For example, if HNSCC is primary site oropharyngeal HNSCC and p16 positive, HNSCC is classified as HPV positive. In some embodiments, HPV status is determined by tumor DNA analysis. For example, HNSCC is HPV negative if HPV DNA or RNA is not detected in HNSCC. For example, HNSCC is HPV positive if HPV DNA or RNA is detected in HNSCC.

[0011] In some embodiments, the HNSCC in the subject has been previously treated with an immunotherapy, such as a PD-1 or PD-L1 checkpoint inhibitor. In some embodiments, the HNSCC is resistant to PD-1 or PD-L1 immunotherapy. In some embodiments, the immunotherapy is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, tremelimumab, or tisotumab. In some embodiments, the immunotherapy is pembrolizumab. In some embodiments, the immunotherapy is nivolumab.

[0012] In some embodiments, the HNSCC has been previously treated with platinum chemotherapy. In some embodiments, the HNSCC is platinum resistant or the subject is unsuitable for platinum chemotherapy. In some embodiments, the platinum chemotherapy is carboplatin, oxaliplatin, cisplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, or satraplatin. In some embodiments, the platinum therapy is carboplatin or cisplatin.

[0013] In some embodiments, the HNSCC in the subject has been previously treated with 5-fluorouracil or other antimetabolite chemotherapy, hi some embodiments, the HNSCC has been previously treated with pembrolizumab, with or without platinum as first-line therapy, and with or without 5-fluorouracil.

[0014] In some embodiments, the HNSCC originates from a primary site in the oral cavity, pharynx, or larynx, hi some embodiments, the HNSCC is hypopharyngeal cancer, laryngeal cancer, lip or oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus or nasal cavity cancer, or salivary gland cancer.

[0015] In some embodiments, the dose of ficlatuzumab is 10 mg / kg to 100 mg / kg. In some embodiments, the dose of ficlatuzumab is 10 mg / kg to 50 mg / kg. In some embodiments, the dose of ficlatuzumab is 20 mg / kg. In some embodiments, the dose of ficlatuzumab is 15 mg / kg. In some embodiments, the dose of ficlatuzumab is 10 mg / kg. In some embodiments, the dose of ficlatuzumab is administered intravenously every 2 weeks. In some embodiments, the dose of ficlatuzumab is administered intravenously every 2 weeks + / - 3 days.

[0016] In some embodiments, the dose of cetuximab is between 250 and 700 mg / m 2 In some embodiments, the dose of cetuximab is between 300 and 500 mg / m 2 In some embodiments, the dose of cetuximab is 500 mg / m 2 In some embodiments, the dose of cetuximab is 400 mg / m 2 In some embodiments, the dose of cetuximab is 300 mg / m 2 In some embodiments, the dose of cetuximab is administered intravenously every two weeks. In some embodiments, the dose of cetuximab is administered intravenously every two weeks + / - 3 days. In some embodiments, the dose of cetuximab and the dose of ficlatuzumab are administered intravenously on the same day, simultaneously or sequentially.

[0017] In some embodiments, the dose of cetuximab is 500 mg / m 2 and the dose of ficlatuzumab is 20 mg / kg, each administered by intravenous infusion either simultaneously or sequentially on the same day every two weeks.

[0018] In some embodiments, cetuximab and ficlatuzumab are administered to a subject until progression, development or new metastases of HNSCC, or until the patient experiences unacceptable toxicity.

[0019] In another aspect, the present invention provides a method of identifying a subject having head and neck squamous cell carcinoma (HNSCC) suitable for combination therapy with ficlatuzumab and cetuximab. In some embodiments, the method of identification includes assessing whether the HNSCC is human papilloma virus (HPV) negative or HPV positive. In some embodiments, if the HNSCC is human papilloma virus (HPV) negative, the subject is identified as suitable for combination therapy.

[0020] In some embodiments, a subject is identified as suitable for combination therapy if the HNSCC is platinum resistant or if the subject is unsuitable for platinum chemotherapy.

[0021] In some embodiments, the subject is identified as suitable for combination therapy if the HNSCC is not responsive to immunotherapy with a PD-1 or PD-L1 inhibitor.

[0022] In some embodiments, if a subject is not suitable for immunotherapy, such as with a PD-1 or PD-L1 inhibitor, the subject is identified as suitable for combination therapy.

[0023] In some embodiments, the subject is identified as suitable for combination therapy if the HNSCC is platinum resistant and not responsive to immunotherapy with a PD-1 or PD-L1 inhibitor. In some embodiments, the subject is identified as suitable for combination therapy if the immunotherapy is pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, tremelimumab, or tisotumab. In some embodiments, the subject is identified as suitable for combination therapy if the immunotherapy is pembrolizumab or nivolumab. In some embodiments, the subject is identified as suitable for combination therapy if the platinum is carboplatin or cisplatin.

[0024] In some embodiments, the method of identifying further comprises, if the subject is identified as suitable for combination therapy, administering the combination therapy to the subject.

[0025] In some embodiments, the HPV status of HNSCC is determined by p16 immunohistochemistry. In some embodiments, if HNSCC is classified as p16 negative, HNSCC is HPV negative. In some embodiments, if HNSCC is classified as p16 positive, HNSCC is HPV positive. In some embodiments, the HPV status of HNSCC is determined by tumor DNA analysis. For example, HNSCC is HPV negative if HPV DNA is not detected in HNSCC. For example, HNSCC is HPV positive if HPV DNA is detected in HNSCC.

[0026] In some embodiments, the HNSCC originates from a primary site in the oral cavity, pharynx, or larynx, hi some embodiments, the HNSCC is hypopharyngeal cancer, laryngeal cancer, lip or oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus or nasal cavity cancer, or salivary gland cancer.

[0027] In some embodiments, the combination therapy is a first line therapy. In some embodiments, the combination therapy is a second line therapy. In some embodiments, the combination therapy is a third line or post-line therapy.

[0028] In some embodiments, the combination therapy comprises administering a dose of ficlatuzumab that is between 10 mg / kg and 100 mg / kg. In some embodiments, the combination therapy comprises administering a dose of ficlatuzumab that is between 10 mg / kg and 50 mg / kg. In some embodiments, the combination therapy comprises administering a dose of ficlatuzumab that is 20 mg / kg. In some embodiments, the combination therapy comprises administering a dose of ficlatuzumab that is 15 mg / kg. In some embodiments, the combination therapy comprises administering a dose of ficlatuzumab that is 10 mg / kg.

[0029] In some embodiments, the combination therapy is 250 to 700 mg / m 2 In some embodiments, the combination therapy comprises administering a dose of cetuximab of 300 to 500 mg / m 2In some embodiments, the combination therapy comprises administering a dose of cetuximab that is 500 mg / m 2 In some embodiments, the combination therapy comprises administering a dose of cetuximab that is 400 mg / m 2 In some embodiments, the combination therapy comprises administering a dose of cetuximab that is 300 mg / m 2 The method includes administering a dose of cetuximab that is

[0030] In some embodiments, the combination therapy comprises administering doses of ficlatuzumab and cetuximab intravenously every two weeks.In some embodiments, the combination therapy comprises administering doses of ficlatuzumab and cetuximab intravenously every two weeks + / - 3 days.

[0031] In some embodiments, the combination therapy includes administering a dose of cetuximab and a dose of ficlatuzumab on the same day, e.g., simultaneously or sequentially.

[0032] In one aspect, the invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject therapeutically effective amounts of an HGF inhibitor and an EGFR inhibitor.

[0033] In certain embodiments, the HGF inhibitor is an anti-HGF antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-HGF antibody or an antigen-binding fragment thereof comprises: (i) a CDR comprising the amino acid sequence of SEQ ID NO:1; H1 , CDR comprising the amino acid sequence of SEQ ID NO:2 H2 and a CDR comprising the amino acid sequence of SEQ ID NO:3. H3 and / or (ii) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4; L1 , CDR comprising the amino acid sequence of SEQ ID NO:5 L2 and a CDR comprising the amino acid sequence of SEQ ID NO:6. L3In certain embodiments, the anti-HGF antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain variable region comprising an amino acid sequence of SEQ ID NO:7, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:7; and (ii) an immunoglobulin light chain variable region comprising an amino acid sequence of SEQ ID NO:8, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:8. In certain embodiments, the anti-HGF antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain comprising an amino acid sequence of SEQ ID NO: 17, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 17; and (ii) an immunoglobulin light chain comprising an amino acid sequence of SEQ ID NO: 18, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, the anti-HGF antibody is selected from the group consisting of rilotumumab, ficlatuzumab, and combinations thereof, for example, the anti-HGF antibody is ficlatuzumab.

[0034] In certain embodiments, the EGFR inhibitor is an anti-EGFR antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-EGFR antibody or an antigen-binding fragment thereof comprises (i) a CDR comprising the amino acid sequence of SEQ ID NO:9. H1 , CDR comprising the amino acid sequence of SEQ ID NO: 10 H2 and a CDR comprising the amino acid sequence of SEQ ID NO:11. H3 and / or (ii) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12; L1 , CDR comprising the amino acid sequence of SEQ ID NO: 13 L2 and a CDR comprising the amino acid sequence of SEQ ID NO: 14. L3In certain embodiments, the anti-EGFR antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 15, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 15; and (ii) an immunoglobulin light chain variable region comprising an amino acid sequence of SEQ ID NO: 16, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 16. In certain embodiments, the anti-EGFR antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain comprising an amino acid sequence of SEQ ID NO: 19, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 19; and (ii) an immunoglobulin light chain comprising an amino acid sequence of SEQ ID NO: 20, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 20. In certain embodiments, the anti-EGFR antibody is selected from the group consisting of cetuximab, futuximab, imgatuzumab, matuzumab, necitumumab, nimotuzumab, panitumumab, amivantamab, zalutumumab, and combinations thereof, e.g., the anti-EGFR antibody is cetuximab.

[0035] The anti-HGF antibody or antigen-binding fragment thereof, or the anti-EGFR antibody or antigen-binding fragment thereof, may be, for example, a Fab, Fv, scFv, Fab', or (Fab')2. In certain embodiments, the anti-HGF antibody or antigen-binding fragment thereof, or the anti-EGFR antibody or antigen-binding fragment thereof, is or is derived from a chimeric antibody, a human antibody, or a humanized antibody.

[0036] The HGF inhibitor (e.g., an anti-HGF antibody or antigen-binding fragment thereof) and the EGFR inhibitor (e.g., an anti-EGFR antibody or antigen-binding fragment thereof) can be administered simultaneously, for example, for at least one cycle of treatment. The HGF inhibitor (e.g., an anti-HGF antibody or antigen-binding fragment thereof) or the EGFR inhibitor (e.g., an anti-EGFR antibody or antigen-binding fragment thereof) can be administered sequentially, for example, for at least one cycle of treatment. In certain embodiments, the HGF inhibitor (e.g., anti-HGF antibody or antigen-binding fragment thereof) is administered after the EGFR inhibitor (e.g., anti-EGFR antibody or antigen-binding fragment thereof) for at least one cycle of treatment, e.g., the HGF inhibitor (e.g., anti-HGF antibody or antigen-binding fragment thereof) is administered at least 15 minutes, at least 30 minutes, at least 60 minutes, at least 120 minutes, at least 180 minutes, at least 240 minutes, or at least 300 minutes, or from about 30 minutes to about 60 minutes, from about 60 minutes to about 120 minutes, or from about 120 minutes to about 180 minutes after the completion of administration of the EGFR inhibitor (e.g., anti-EGFR antibody or antigen-binding fragment thereof). In certain embodiments, the HGF inhibitor (e.g., anti-HGF antibody or antigen-binding fragment thereof) is administered simultaneously with the EGFR inhibitor (e.g., anti-EGFR antibody or antigen-binding fragment thereof), e.g., for at least one cycle of treatment. For example, an HGF inhibitor, such as ficlatuzumab, and an EGFR inhibitor, such as cetuximab, are administered simultaneously, for example, by intravenous infusion.

[0037] In certain embodiments, the HGF inhibitor (e.g., anti-HGF antibody or antigen-binding fragment thereof) and the EGFR inhibitor (e.g., anti-EGFR antibody or antigen-binding fragment thereof) are administered about once a week, about once every two weeks, about once every three weeks, or about once every four weeks, respectively. The HGF inhibitor (e.g., anti-HGF antibody or antigen-binding fragment thereof) and / or the EGFR inhibitor (e.g., anti-EGFR antibody or antigen-binding fragment thereof) can be administered, for example, by intravenous infusion. For example, the HGF inhibitor, for example, ficlatuzumab, and the EGFR inhibitor, for example, cetuximab, are administered simultaneously, for example, by intravenous infusion, every two weeks.

[0038] Conceivable doses of HGF inhibitors (e.g., anti-HGF antibodies or antigen-binding fragments thereof, such as ficlatuzumab) include about 2 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, or about 25 mg / kg. Conceivable doses of EGFR inhibitors (e.g., anti-EGFR antibodies or antigen-binding fragments thereof, such as cetuximab) include about 200 mg / m 2 , about 250mg / m 2 , about 300mg / m 2 , about 400mg / m 2 , about 500mg / m 2 , about 600mg / m 2 , about 700mg / m 2 , or about 800 mg / m 2 Includes:

[0039] In certain embodiments, the method includes administering to a subject: (i) 20 mg / kg of ficlatuzumab (e.g., about every 2 weeks); and (ii) 500 mg / m 2 of cetuximab (e.g., about every two weeks).

[0040] In another aspect, the invention provides a composition comprising (i) an HGF inhibitor (e.g., an anti-HGF antibody or antigen-binding fragment thereof, e.g., an anti-HGF antibody or antigen-binding fragment thereof disclosed herein), (ii) an EGFR inhibitor (e.g., an anti-EGFR antibody or antigen-binding fragment thereof, e.g., an anti-EGFR antibody or antigen-binding fragment thereof disclosed herein), and optionally (iii) a pharmaceutically acceptable carrier.

[0041] The present invention may be more fully understood in connection with the following drawings. [Brief description of the drawings]

[0042] [Figure 1] 1 shows the study protocol for the Phase II study described in Example 1 to determine the efficacy of treating subjects with recurrent or metastatic HNSCC with ficlatuzumab alone or in combination with cetuximab. [Diagram 2]FIG. 1 shows the patient disposition for the Phase II study described in Example 1 to determine the efficacy of treating subjects with recurrent or metastatic HNSCC with ficlatuzumab alone or in combination with cetuximab, and presents the overall response rate (ORR) for each study arm, including the ORR for the patient population when stratified by HPV status. [Diagram 3]

[0023] Figure 1 presents a breakdown of baseline demographics of subjects with recurrent or metastatic HNSCC participating in the Phase II study described in Example 1 to determine the efficacy of treating those subjects with ficlatuzumab alone or in combination with cetuximab. [Figure 4]

[0023] Figure 1 provides a classification of the types of toxicity experienced by subjects with recurrent or metastatic HNSCC participating in the Phase II study described in Example 1 to determine the efficacy of treating those subjects with ficlatuzumab alone or in combination with cetuximab. Toxicities are classified as cardiovascular, constitutional, dermatological, gastrointestinal, metabolic, or pulmonary, and the percentage of each type, grade 1-2 or grade 3, is presented according to treatment type (i.e., ficlatuzumab vs. ficlatuzumab and cetuximab). [Figure 5A] 1 is a Kaplan-Meier curve showing progression-free survival (PFS) stratified by treatment versus control arm for the patient population in the Phase II trial described in Example 1. The tail of the ficlatuzumab + cetuximab (treatment) arm extends beyond 15 months. [Figure 5B] 1 is a Kaplan-Meier curve showing overall survival data stratified by treatment versus control arm for the patient population in the Phase II trial described in Example 1. The tail for the ficlatuzumab + cetuximab arm (treatment) extends beyond 15 months. [Figure 6A] FIG. 1 shows overall response rate (ORR) and median progression-free survival (mPFS) for patient populations stratified by HPV status (HPV+ and HPV- subgroups) in the treatment arms (ficlatuzumab + cetuximab) of the Phase II study described in Example 1 (PR=partial response; CR=complete response). [Figure 6B]Kaplan-Meier curves of progression-free survival (PFS) stratified by HPV status (HPV+ and HPV- subgroups) for the treatment arms (ficlatuzumab + cetuximab) of the Phase II trial described in Example 1. The tail for the HPV- subgroup extends beyond 15 months. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0043] The present invention relates to improved methods of treating subjects with cancer, such as head and neck squamous cell carcinoma (HNSCC).

[0044] Head and neck squamous cell carcinoma (HNSCC) is a morbid and fatal cancer resulting from habitual exposure to tobacco and other carcinogens or human papillomavirus (HPV). In 2021, over 65,000 people in the United States and over 700,000 people worldwide are expected to suffer from HNSCC. 90% of patients with HPV-positive or HPV-negative HNSCC present with disease localized to the head and neck. Initial treatment of localized disease, referred to as curative or curative therapy, includes surgical resection, radiation, and systemic therapy. However, recurrence after curative multimodality treatment is approximately 20% and 50%, respectively. Overall survival in the face of recurrent / metastatic disease is less than 2 years. Treatment of recurrent / metastatic disease is referred to as palliative therapy. For palliative treatment of recurrent / metastatic disease, first-line systemic options include anti-programmed death receptor 1 (PD-1) immune checkpoint inhibitors, such as pembrolizumab, with or without platinum and 5-fluorouracil cytotoxic chemotherapy. In the second-line or back-line, available therapies include anti-microtubule taxane chemotherapy, the antimetabolite methotrexate, and the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), cetuximab, with single-agent response rates of approximately 5-15%.

[0045] Head and neck squamous cell carcinoma (HNSCC) arises from the mucosal epithelium within the oral cavity, pharynx, larynx, and paranasal passages (paranasal sinuses and nasal cavity) and is the most common malignant tumor occurring in the head and neck. The oral cavity includes the gums, lips, buccal mucosa (the inner surface of the cheeks and behind the lips), hard palate (the upper bony part of the mouth), anterior tongue, floor of the mouth (under the tongue), and retromolar triangle. The pharynx (throat) includes the nasopharynx, oropharynx (palatine tonsils, lingual tonsils, base of tongue, soft palate, uvula, and posterior wall of the pharynx), and hypopharynx (lower part of the throat extending from the hyoid bone to the cricoid cartilage), and larynx. HNSCC can arise in any of these primary sites. HNSCC can also arise in the salivary glands. HNSCC tumors arising in any of these sites can be treated by the methods of the invention disclosed herein. HNSCC includes, for example, hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharynx cancer, paranasal sinus and nasal cavity cancer, and salivary gland cancer. These are exemplary types of HNSCC that can be treated by the methods of the present invention disclosed herein. However, squamous cell carcinoma of unknown primary site, apparently related to the head and neck, can be treated by the methods of the present invention.

[0046] HNSCC tumors typically result from prior infection with oncogenic strains of human papillomavirus (HPV), such as HPV-16 or HPV-18, as well as other strains, or from smoking or regular tobacco use. HPV-negative HNSCC of the oral cavity and larynx is primarily due to smoking or regular tobacco use. HNSCC caused by HPV (HPV-positive) typically occurs in the palate and lingual tonsils of the oropharynx, while HNSCC associated with regular tobacco use is found primarily in the oral cavity, hypopharynx, and larynx.

[0047] An important finding of the Phase II study described in Example 1 herein below is that HNSCC subjects whose tumors were HPV-negative had a better outcome with treatment with ficlatuzumab in combination with cetuximab compared to subjects with HPV-positive HNSCC. Indeed, the data presented in Example 1 show that among HPV-positive HNSCC subjects, there were no responders in the combination group (ficlatuzumab and cetuximab), and all responders (complete and partial responses) had HPV-negative HNSCC. In the ficlatuzumab alone group, the only responders were HPV-negative, and there were no HPV-positive responders. This result was surprising, since historically, HPV-positive HNSCC subjects typically have better outcomes than HPV-negative HNSCC subjects. Indeed, HPV negativity is considered a poor prognostic indicator for HNSCC patients, including those treated with cetuximab according to the current standard of care in second-line or back-line therapy. It is therefore entirely surprising and unexpected that HPV-negative status for treatment with the methods of the present invention can be a positive prognostic indicator, while HPV-positive status can be a negative prognostic indicator.

[0048] Thus, among other things, the data presented herein suggests that HPV-negative HNSCC subjects should be selected for treatment with ficlatuzumab and cetuximab, while HPV-positive HNSCC should not be selected for treatment with ficlatuzumab and cetuximab.Furthermore, the data suggests that cetuximab with ficlatuzumab may replace cetuximab alone, which is the current standard of care for second-line or back-line therapy in subjects with HPV-negative HNSCC.For example, in HNSCC subjects who have progressed after treatment with immunotherapy (e.g., PD-1, PD-L1 or other checkpoint inhibitors) or other first-line treatments that would be the standard of care if their HNSCC were HPV-, those subjects may be treated with ficlatuzumab and cetuximab according to the methods of the invention disclosed herein, rather than being treated with cetuximab alone. Thus, in some embodiments of the invention, a subject treated with ficlatuzumab and cetuximab according to the methods of the invention is cetuximab naive, meaning that he has not been previously treated with cetuximab.In some embodiments of the invention, a subject with HNSCC treated with ficlatuzumab and cetuximab according to the methods of the invention is cetuximab resistant, meaning that his HNSCC has been previously treated with cetuximab, but the HNSCC has recurred or metastasized.

[0049] According to one embodiment of the invention, a subject with HNSCC is treated with the methods of the invention (e.g., with ficlatuzumab and cetuximab) if the subject is identified as having HPV-negative HNSCC. In one embodiment, the subject is cetuximab treatment naive.

[0050] According to one embodiment of the invention, a subject with recurrent or metastatic HNSCC is treated with the methods of the invention (e.g., with ficlatuzumab and cetuximab) if identified as having HPV-negative HNSCC. In one embodiment, the subject is cetuximab treatment naive.

[0051] According to some embodiments of the invention, a subject with HNSCC is identified as having HPV-negative HNSCC and is treated with the methods of the invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is resistant to treatment with immunotherapy (e.g., immune checkpoint inhibitor therapy such as pembrolizumab), e.g., the HNSCC is immune checkpoint inhibitor, PD-L1, or PD-1 resistant. In some embodiments, the subject may also have been treated with radiation. In one embodiment, the subject is cetuximab naive. In some embodiments, the HNSCC has not been treated with platinum, and thus is platinum naive or the subject is platinum ineligible.

[0052] According to some embodiments of the invention, a subject with HNSCC is identified as having HPV-negative HNSCC and is treated with the methods of the invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is resistant to immunotherapy (e.g., immune checkpoint inhibitor therapy such as pembrolizumab) and has been previously treated with platinum chemotherapy (e.g., cisplatin or carboplatin). In some embodiments, the subject may also have been previously treated with radiation. In some embodiments, the HNSCC is also platinum-resistant. In one embodiment, the subject is cetuximab naive.

[0053] According to one embodiment of the invention, a subject with recurrent or metastatic HNSCC is identified as having HPV-negative HNSCC and is treated by the methods of the invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is resistant to treatment with immunotherapy (e.g., immune checkpoint inhibitor therapy such as pembrolizumab), e.g., the HNSCC is immune checkpoint inhibitor, PD-L1, or PD-1 resistant. In some embodiments, the subject may also have been previously treated with radiation. In one embodiment, the subject is cetuximab naive. In some embodiments, the HNSCC has not been previously treated with platinum, and thus is platinum naive or the subject is platinum ineligible.

[0054] According to one embodiment of the invention, a subject with recurrent or metastatic HNSCC is identified as having HPV-negative HNSCC and is treated with the methods of the invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is resistant to immunotherapy (e.g., immune checkpoint inhibitor therapy such as pembrolizumab) and has been previously treated with platinum chemotherapy (e.g., cisplatin or carboplatin). In some embodiments, the subject may also have been previously treated with radiation. In some embodiments, the HNSCC is also platinum-resistant. In one embodiment, the subject is cetuximab naive.

[0055] According to one embodiment of the present invention, a subject with recurrent or metastatic HNSCC is identified as having HPV-negative HNSCC and is treated with the methods of the present invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is platinum-resistant. In some embodiments, the subject may also have a history of treatment with radiation. In some embodiments, the subject is immunotherapy (e.g., immune checkpoint inhibitor therapy such as pembrolizumab) ineligible or immunotherapy treatment naive (e.g., has not previously received immunotherapy, e.g., immune checkpoint inhibitor therapy such as pembrolizumab, e.g., is immune checkpoint or PD-1 or PD-L1 treatment naive). In one embodiment, the subject is cetuximab treatment naive.

[0056] According to one embodiment of the present invention, a subject with recurrent or metastatic HNSCC is identified as having HPV-negative HNSCC and is treated with the methods of the present invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is platinum-resistant. In some embodiments, the subject may also have a history of treatment with radiation. In some embodiments, the HNSCC may further be resistant to immunotherapy (e.g., immune checkpoint inhibitor therapy such as pembrolizumab) or the subject has been treated with immunotherapy (e.g., immune checkpoint inhibitor therapy such as pembrolizumab). In some embodiments, the subject is immunotherapy ineligible (e.g., immune checkpoint inhibitor therapy, e.g., PD-1 or PD-L1 ineligible) or the subject may not have been previously treated with immunotherapy and is therefore immunotherapy treatment naive. In one embodiment, the subject is cetuximab treatment naive.

[0057] According to one embodiment of the present invention, a subject having HNSCC, e.g., recurrent or metastatic HNSCC, is identified as having HPV-negative HNSCC and is treated with the methods of the present invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is platinum-resistant and immunotherapy-resistant. In one embodiment, the subject is cetuximab treatment naive. In some embodiments, a subject having HNSCC, recurrent or metastatic HNSCC, is identified as having HPV-negative HNSCC and is treated with the methods of the present invention (e.g., with ficlatuzumab and cetuximab) if the HNSCC is platinum-resistant and / or immunotherapy-resistant. In some embodiments, the immunotherapy comprises an immune checkpoint inhibitor therapy as described herein. In some embodiments, the HNSCC may also have been previously treated with radiation.

[0058] In some embodiments, the platinum-resistant HNSCC is resistant to carboplatin, oxaliplatin, cisplatin, nedaplatin, lobaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, or satraplatin, or a combination thereof, hi some embodiments, the platinum-resistant HNSCC is resistant to carboplatin or cisplatin, or a combination thereof.

[0059] In some embodiments, the immunotherapy-resistant HNSCC is resistant to checkpoint inhibitors. In some embodiments, the immune checkpoint inhibitors may include a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a VISTA inhibitor, a KIR inhibitor, a 2B4 inhibitor, a CD160 inhibitor, a CGEN-15049 inhibitor, a CHK1 inhibitor, a CHK2 inhibitor, an A2aR inhibitor, or any combination thereof.

[0060] In some embodiments, the PD-1 inhibitor may include nivolumab, pembrolizumab, pidilizumab, REGN2810, PDR001, or any combination thereof. In some embodiments, the PD-L1 inhibitor may include durvalumab, atezolizumab, avelumab, or any combination thereof. In some embodiments, the CTLA-4 inhibitor may include ipilimumab, tremelimumab, AGEN-1884, or any combination thereof. In some embodiments, the TIM-3 inhibitor may include TSR-022, LY3321367, MBG453, or any combination thereof. In some embodiments, the TIGIT inhibitor may include BMS-986207, AGEN17, tiragolumab, MK-7684, OMP-313M32, EOS-448, AB154, or any combination thereof. In some embodiments, LAG-3 inhibitors may include BMS-986016, REGN3767, IMP321, LAG525, BI754111, favezelimab, or combinations thereof. In some embodiments, VISTA inhibitors may include CI-8993, HMBD-002, PSGL-1 antagonists described in WO2018 / 132476, or combinations thereof.

[0061] In one aspect, the present invention provides a method for treating cancer in a subject in need of treatment. The method comprises administering to the subject a therapeutically effective amount of an HGF inhibitor and an EGFR inhibitor. In another aspect, the present invention provides a composition comprising an HGF inhibitor, an EGFR inhibitor, and optionally a pharma- ceutically acceptable carrier. In another aspect, the present invention provides a method for identifying a subject with HNSCC suitable for combination therapy comprising an HGF inhibitor and an EGFR inhibitor.

[0062] I. Definition For convenience, certain terms from the specification, examples, and appended claims are collected in this section.

[0063] As used herein, "pharmacologically acceptable" or "pharmacologically acceptable" refers to molecular entities and compositions that do not produce harmful, allergic, or other untoward reactions when administered to animals or humans, as appropriate. The term "pharmacologically acceptable carrier" includes any solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients may also be incorporated into the compositions.

[0064] As used herein, the term "progression-free survival (PFS)" is defined as the time from randomization to first documentation of objective tumor progression by RECIST (version 1.1; see, e.g., Eisenhauer et al. (2009), EUR. J. CANCER, 25:228-247) (progressive disease, "PD", radiology) or death from any cause, whichever occurs first.

[0065] As used herein, the term "overall survival (OS)" is defined as the period from the date of randomization to the date of death from any cause.

[0066] As used herein, the term "objective response rate (ORR)" is defined as the proportion of subjects with a confirmed complete response (CR) or confirmed partial response (PR) by RECIST (version 1.1) out of the total number of randomized subjects. A confirmed response is one that persists on a repeat imaging study at least 4 weeks after the initial documentation of the response.

[0067] As used herein, the term "duration of response (DoR)" is defined as the time from first documentation of an objective tumor response (either complete response or partial response, whichever is first documented) to first documentation of objective tumor progression or death from any cause.

[0068] As used herein, the term "response" or "responding" in the context of a subject's response to a treatment refers to RECIST (Response Evaluation Criteria in Solid Tumors, ver. 1.1, 2009) criteria for assessing the response of a target lesion to cancer therapy. According to the RECIST criteria, responding subjects are classified as either "complete responders" (disappearance of all target lesions; any pathological lymph nodes (target or non-target) must have a reduction in their short axis to <10 mm) or "partial responders" (at least a 30% decrease in the sum of the long diameters of the target lesions, based on the baseline sum of the long diameters); non-responders are placed in one of two categories: stable disease (neither sufficient reduction to qualify as a partial response, nor sufficient increase to qualify as progressive disease, based on the smallest sum of the long diameters since the start of treatment); or progressive disease (at least a 20% increase in the sum of the long diameters of the target lesions, based on the smallest sum of the long diameters recorded since the start of treatment, or the appearance of one or more new lesions; baseline sum of diameters measurement; the sum must also show an absolute increase of at least 5 mm in addition to a relative increase of 20%). RECIST criteria are discussed in detail, for example, in Therasse et al., J. NATL. CANCER INST., 2000:92:205-216 (RECIST 1.0), and Eisenhauer et al., EUR. J. CANCER, 2009:25:228-247 (RECIST 1.1). Thus, as described herein, a response to a therapy refers to a subject falling within the RECIST categories for a complete responder or partial responder, and a non-response refers to a subject falling within the RECIST categories for stable or progressive disease.

[0069] As used herein, the terms "drug-related adverse event," "adverse event," or "AE" refer to adverse events as defined and classified in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, dated June 14, 2010, and any reference to the "grade" of an adverse event refers to the grading system outlined therein.

[0070] As used herein, the terms "treating" or "treat" or "treatment" in the context of cancer refers to the application of a technique, action, or therapy to a subject that (a) slows tumor growth, (b) halts tumor growth, (c) promotes tumor regression or elimination, (d) ameliorates the symptoms of cancer, (e) cures cancer, or (f) prolongs the survival of the subject, or the application of a technique, action, or therapy to a subject in an attempt to accomplish any of (a)-(f), regardless of whether the individual actually responds to the technique, action, or therapy.

[0071] The term "clinical benefit" as used herein refers to a subject experiencing any of the following: (a) a slowing of tumor growth; (b) halting of tumor growth; (c) tumor regression or elimination; (d) amelioration of symptoms of cancer; (e) curing the cancer; or (f) prolongation of the subject's survival.

[0072] As used herein, "progression" with respect to a cancer or tumor (e.g., HNSCC) refers to a cancer or tumor that has reached stage 3 or stage 4. In certain embodiments, "progression" means that the cancer or tumor has metastasized or cannot be adequately treated by local therapy alone, such as surgical intervention or radiation therapy, and therefore requires systemic therapy. In certain embodiments, "progression" means that the cancer or tumor has recurred after responding to treatment with local or systemic therapy.

[0073] As used herein, "pan-refractory" HNSCC refers to HNSCC that is resistant to or not suitable for treatment with each of: (i) platinum chemotherapy, (ii) immunotherapy (e.g., checkpoint inhibitors), and (iii) cetuximab.

[0074] As used herein, a "recurrent" cancer (e.g., recurrent HNSCC) refers to a cancer that does not respond to treatment or returns to its original state after treatment, i.e., "recurs." For example, a cancer is recurrent if it does not respond to a treatment modality, e.g., the subject does not achieve clinical benefit during treatment, or the disease progresses. For example, a cancer is recurrent if it returns to its original state or progresses after treatment. As used herein, a "recurrent" cancer can be a cancer that responds to an initial treatment and then returns to its original state, or a cancer that initially responds to a treatment but ceases to respond to such treatment or develops resistance at a later stage of treatment. In certain embodiments, "recurrent" refers to a cancer or tumor, such as, e.g., HNSCC, that has been treated with at least one systemic or local treatment and has failed to respond to or become resistant to such treatment, or that continues to progress during or after such treatment. In other embodiments, "recurrent" refers to a cancer or tumor, such as HNSCC, that has been treated with at least two systemic or local treatments and has failed to respond to or become resistant to such treatment, or continues to progress during or after such treatment. In some embodiments, HNSCC is "recurrent" if it has not responded to curative or curative therapy and requires palliative therapy. In some scientific contexts, HNSCC that is recurrent may be described as "resistant" or "refractory."

[0075] As used herein, "metastatic" cancer (e.g., metastatic HNSCC) refers to cancer that has spread from the part of the body where it began (i.e., the primary site) to other parts of the body. For example, metastatic HNSCC refers to an HNSCC primary site tumor that has spread to other parts of the body. In some embodiments, metastatic HNSCC requires palliative therapy.

[0076] As used herein, the terms "subject" and "patient" are used interchangeably and refer to an organism that is treated by the methods and compositions of the present invention. Such an organism is preferably a mammal (e.g., a human, a mouse, a rat, a guinea pig, a dog, a cat, a horse, a cow, a pig, or a non-human primate such as a monkey, a chimpanzee, a baboon, and a rhesus monkey), and more preferably a human.

[0077] The term "pharmaceutical composition" as used herein refers to a combination of an active agent with a carrier, inert or active, making the composition particularly suitable for in vivo or ex vivo diagnostic or therapeutic uses.

[0078] As used herein, the term "effective amount" refers to an amount of an active agent (e.g., an HGF inhibitor and / or an EGFR inhibitor) sufficient to achieve a useful or desired result, e.g., to achieve a clinical benefit in a subject. An effective amount may be administered in one or more administrations, applications or doses, and is not intended to be limited to a particular formulation or route of administration.

[0079] The term "resistant" as used herein refers to a cancer or tumor that does not respond to a certain anti-cancer therapy. In some embodiments, a cancer or tumor is "resistant" if it stops responding to a treatment at some point during the course of treatment after previously responding to the treatment, or a cancer or tumor can be "resistant" because it has never responded to a course of treatment, e.g., is non-responsive to a treatment from the beginning of a course of treatment. In some embodiments, a cancer or tumor is also "resistant" if it recurs or progresses after a course of treatment is completed. In some embodiments, a cancer or tumor is also "resistant" if it recurs or progresses during a course of treatment. For example, a "platinum-resistant" cancer or tumor, e.g., HNSCC, is one that does not respond or stops responding to platinum chemotherapy, e.g., carboplatin or cisplatin. For example, an immunotherapy-resistant cancer or tumor, e.g., HNSCC, is one that does not respond or stops responding to immunotherapy, e.g., checkpoint inhibitors such as PD-1 or PD-L1 inhibitors, e.g., pembrolizumab. For example, an HNSCC that does not respond or ceases to respond to a checkpoint inhibitor is a "checkpoint inhibitor resistant" HNSCC. Additionally, a cancer or tumor that "fails" or is "non-responsive" to immunotherapy, such as an HNSCC, can be synonymous with an HNSCC that is "immunotherapy resistant." A cancer or tumor that "fails" or is "non-responsive" to platinum chemotherapy, such as an HNSCC, is considered synonymous with an HNSCC that is "platinum resistant."

[0080] As used herein, the term "platinum ineligible" refers to a subject who, for any reason, is ineligible to receive platinum chemotherapy as a treatment for cancer, such as HNSCC. For example, a subject may be platinum ineligible because of impaired renal or hepatic function, or because of cumulative toxicity.

[0081] As used herein, the term "immunotherapy ineligible" refers to a subject who, for any reason, is ineligible to receive immunotherapy, such as a checkpoint inhibitor, e.g., a PD-1 or PD-L1 inhibitor, as a treatment for a cancer, such as HNSCC. For example, a subject may be immunotherapy ineligible because they have an autoimmune disorder.

[0082] The methods and compositions described herein may be used alone or in combination with other therapeutic agents and / or modalities. The term "concomitantly administered" as used herein is understood to mean that two (or more) different treatments are delivered to a subject in such a way that the effects of the treatments overlap at a time during the course of the subject's suffering from a disorder. In certain embodiments, there is an overlap in terms of administration because the delivery of one treatment is still occurring when the delivery of the second treatment begins. This may also be referred to herein as "simultaneous" or "concurrent delivery". In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In certain embodiments in either case, the treatment is more effective due to the combined administration. For example, the second treatment is more effective, e.g., a comparable effect is seen with a smaller amount of the second treatment, or the second treatment relieves symptoms to a greater extent than would be seen if administered in the absence of the first treatment, or a similar situation is seen with the first treatment. In certain embodiments, the delivery is such that the reduction in symptoms or other parameters associated with the disorder is more significant than would be observed with one treatment delivered in the absence of the other treatment. The effects of the two treatments may be partially additive, fully additive, or greater than additive. The delivery may be such that the effect of the first treatment delivered is still detectable upon delivery of the second treatment.

[0083] The term "antibody" as used herein, unless otherwise indicated, is understood to mean an intact antibody (e.g., an intact monoclonal antibody), or a fragment thereof, such as an Fc fragment of an antibody (e.g., an Fc fragment of a monoclonal antibody), or an antigen-binding fragment of an antibody (e.g., an antigen-binding fragment of a monoclonal antibody), including an intact antibody, an antigen-binding fragment, or a modified, engineered, or chemically conjugated Fc fragment. Examples of antigen-binding fragments include Fab, Fab', (Fab')2, Fv, single-chain antibodies (e.g., scFv), minibodies, and diabodies. Examples of modified or engineered antibodies include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies). One example of a chemically conjugated antibody is an antibody conjugated to a toxin moiety.

[0084]

[0033] Throughout the specification where compositions are described as having, including, or comprising particular components, or processes and methods are described as having, including, or comprising particular steps, it is contemplated that there are further compositions of the invention which consist essentially of or consist of the recited components, and that there are processes and methods according to the invention which consist essentially of or consist of the recited processing steps.

[0085] In applications where an element or component is said to be included in and / or selected from a list of recited elements or components, it is understood that the element or component can be any one of the recited elements or components, or the element or component can be selected from the group consisting of two or more of the recited elements or components.

[0086] Furthermore, it is understood that the elements and / or features of the compositions or methods described herein can be combined in various ways without departing from the spirit and scope of the invention, whether expressly or implicitly described herein. For example, when a particular compound is mentioned, unless otherwise understood from the context, that compound can be used in various embodiments of the compositions of the invention and / or in the methods of the invention. In other words, within the scope of this application, the embodiments have been described and depicted in a manner that allows for a clear and concise application to be written, but it is intended and will be understood that the embodiments can be combined or separated in various ways without departing from the present teachings and invention. For example, it will be understood that all features described and depicted herein are applicable to all aspects of the invention described and depicted herein.

[0087] The phrase "at least one of" is understood to include each of the listed objects following the phrase individually, and various combinations of two or more of the listed objects, unless otherwise understood from context and usage. The phrase "and / or" in the context of more than two listed objects is understood to have the same meaning, unless otherwise understood from context.

[0088] Use of the terms "include," "includes," "including," "have," "has," "having," "contain," "contains," or "containing," including grammatical equivalents thereof, is generally understood to be open-ended and non-limiting, e.g., not excluding additional, unrecited elements or steps, unless specifically recited or otherwise understood from the context.

[0089] When the term "about" is used before a quantitative value, the present invention also includes the specific quantitative value itself, unless otherwise specifically stated. As used herein, the term "about" refers to a ±10% variation from the nominal value, unless otherwise indicated or inferred. For example, "about 10" is a disclosure of the value 10, as well as a range of 10±10%.

[0090] It will be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions may be performed simultaneously.

[0091] Any examples or use of exemplary language herein, such as "such as" or "including," are intended merely to better illustrate the invention and do not limit the scope of the invention unless claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0092] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an antibody" includes a plurality of antibodies, in some embodiments, reference to "the antibody" includes a plurality of antibodies, and so forth.

[0093] All numerical values ​​or ranges used herein include all integers within or including such ranges, and decimals within or including such ranges, unless the context clearly dictates otherwise. Thus, for example, a reference to a range of 90-100% includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth. In other examples, references to a range of 1 to 5,000 fold include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 fold, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5 fold, etc., 2.1, 2.2, 2.3, 2.4, 2.5 fold, etc., and so forth.

[0094] II. HGF inhibitors 1) HGF / c-Met in cancer The MET oncogene encodes c-Met, a RTK that is exclusively bound by the ligand, hepatocyte growth factor (HGF). HGF is also known as "scatter factor," a name that arose from the early observation that HGF promotes cellular decoupling and motility. Overexpression of c-Met is transformative to normal cells, enhancing motility, invasion / metastasis, and angiogenesis (Peruzzi, B. and Bottaro, DP Clin Cancer Res. (2006) 12:3657-3660). MET is a well-established driver of epithelial-mesenchymal transition.

[0095] c-Met and / or HGF are overexpressed in approximately 80% of HNSCC (Knowles, LM et al., Clin Cancer Res. (2009) 15:3740-3750), and MET amplification has been reported in 13% of HNSCC tumors (Seiwert, TY et al., Cancer Res. (2009) 69:3021-3031). Furthermore, several mutations have been identified in the MET oncogene in HNSCC, including alterations in the semaphorin ligand binding, juxtamembrane, and RTK domains (Seiwert, TY et al., Cancer Res. (2009) 69:3021-3031). Although the Swiss Chemoradiotherapy Trial of Locally Advanced Disease described an activating point mutation (Y1253D) in 14% of patients that predicted reduced metastasis-free survival, two whole-exome sequencing projects did not confirm the presence of this mutation in HNSCC (Ghadjar, P. et al., Clin Exp Metastasis. (2009) 26:809-815; Stransky, N. et al., Science (2011) 333:1157-1160; Agrawal, N. et al., Science (2011) 333:1154-1157).

[0096] 2) HGF inhibitors It is contemplated that various HGF inhibitors can be used in the practice of the present invention. The inhibitor can completely or partially inhibit or reduce a given HGF activity or a given HGF-mediated activity compared to an untreated control sample (e.g., tissue sample or body fluid sample) or subject. For example, a particular HGF inhibitor can act by blocking, reducing, or neutralizing the binding between HGF and HGF ligand (e.g., c-Met). It is understood that an HGF inhibitor can block, reduce, or neutralize the binding between HGF and HGF ligand by directly or indirectly binding to HGF, or alternatively by directly or indirectly binding to HGF ligand (e.g., c-Met). Alternatively or additionally, an HGF inhibitor can act by reducing the expression of HGF or HGF ligand (e.g., c-Met). Alternatively or additionally, an HGF inhibitor can directly or indirectly inhibit the downstream effect of the interaction between HGF and HGF ligand (e.g., c-Met).

[0097] Exemplary HGF inhibitors include antibodies, nucleic acid-based therapeutics that bind to a target of interest, such as HGF, such as aptamers and spiegelmers, or antisense or siRNA molecules or CRISPR systems that inhibit expression and / or activity of a target of interest, such as HGF, or small molecule inhibitors, such as small molecule inhibitors of HGF, or combinations thereof.

[0098] It is understood that in certain embodiments, different HGF inhibitors may be administered in combination.

[0099] 3) Anti-HGF antibody In certain embodiments, the HGF inhibitor is an anti-HGF antibody or an antigen-binding fragment thereof.

[0100] Generally, antibodies are multimeric proteins containing four polypeptide chains. Two of the polypeptide chains are called immunoglobulin heavy chains (H chains) and two of the polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are linked by interchain disulfide bonds. The immunoglobulin heavy chains are linked by interchain disulfide bonds. The light chains contain one variable region (V L ) and one constant region (C L The heavy chain consists of one variable region (V H ) and at least three constant regions (CH1, CH2, and CH3). The variable regions determine the binding specificity of the antibody.

[0101] Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs), flanked by four relatively conserved regions known as framework regions (FRs). The extent of the FRs and CDRs has been defined (Kabat, EA et al. (1991) SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242; and Chothia, C. et al. (1987) J. MOL. BIOL. 196:901-917). The three CDRs, called CDR1, CDR2 and CDR3, contribute to the antibody binding specificity. Natural antibodies are used as starting materials for engineered antibodies, such as chimeric and humanized antibodies.

[0102] As disclosed herein, the antibodies of the invention comprise: (a) structural CDRs H1 -CDR H2 -CDR H3 and (b) an immunoglobulin heavy chain variable region comprising the structural CDR L1 -CDR L2 -CDR L3 wherein the heavy chain variable region and / or the light chain variable region together define a single binding site for binding HGF.

[0103] In certain embodiments, the anti-HGF antibody comprises a CDR comprising the amino acid sequence of SEQ ID NO:1. H1 , CDR comprising the amino acid sequence of SEQ ID NO:2 H2 and a CDR comprising the amino acid sequence of SEQ ID NO:3. H3 An immunoglobulin heavy chain variable region including the CDR H1 , CDR H2 , and CDR H3 the sequence is interposed between the immunoglobulin FR sequences; and / or the CDR comprises the amino acid sequence of SEQ ID NO:4 L1 , CDR comprising the amino acid sequence of SEQ ID NO:5 L2 and a CDR comprising the amino acid sequence of SEQ ID NO:6. L3 An immunoglobulin light chain variable region including the CDR L1 , CDR L2 , and CDR L3 The sequences may include intervening immunoglobulin FR sequences.

[0104] In certain embodiments, the anti-HGF antibody comprises a CDR comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:1. H1 CDRs comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:2. H2 and a CDR comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:3. H3 An immunoglobulin heavy chain variable region including the CDR H1 , CDR H2 , and CDR H3 the CDR sequence is interposed between the immunoglobulin FR sequences; and / or the CDR comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:4. L1CDRs comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:5. L2 and a CDR comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:6. L3 An immunoglobulin light chain variable region including the CDR L1 , CDR L2 , and CDR L3 The sequences may include intervening immunoglobulin FR sequences.

[0105] In certain embodiments, the anti-HGF antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7, and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:8.

[0106] In certain embodiments, the anti-HGF antibody comprises an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the entire variable region and / or framework region sequence of the amino acid sequence of SEQ ID NO: 7. In certain embodiments, the anti-HGF antibody comprises an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the entire variable region and / or framework region sequence of the amino acid sequence of SEQ ID NO: 8.

[0107] Sequence identity can be determined in a variety of ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. BLAST (Basic Local Alignment Search Tool) analysis using the algorithms utilized by the programs blastp, blastn, blastx, tblastn, and tblastx (Karlin et al. (1990) PROC. NATL. ACAD. SCI. USA 87:2264-2268; Altschul (1993) J. MOL. EVOL. 36, 290-300; Altschul et al. (1997) NUCLEIC ACIDS RES. 25:3389-3402, all of which are incorporated by reference) has been adapted for sequence similarity searching. For a discussion of basic issues in searching sequence databases, see Altschul et al. (1994) NATURE GENETICS 6:119-129, which is incorporated by reference in its entirety. Those skilled in the art can determine appropriate parameters for alignment measurement, including any algorithms required to achieve the best alignment over the entire length of the sequences being compared. Search parameters for histogram, description, alignment, expectation (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix, and filter are at default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al. (1992) PROC. NATL. ACAD. SCI. USA 89:10915-10919, which is incorporated by reference in its entirety). The four blastn parameters can be adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every wink.sup.th position along the query); and gapw=16 (sets the window width within which gapped alignments are generated).Equivalent Blastp parameter settings would be Q=9; R=2; wink=1; and gapw=32. Searches can also be performed using NCBI (National Center for Biotechnology Information) BLAST Advanced Option parameters (e.g.: -G, cost for gapping [integer]: default=5 for nucleotides / 11 for proteins; -E, cost for extending a gap [integer]: default=2 for nucleotides / 1 for proteins; -q, penalty for nucleotide mismatch [integer]: default=-3; -r, reward for a nucleotide match [integer]: default=1; -e, expectation [real]: default=10; -W, word size [integer]: default=11 for nucleotides / 28 for megablast / 3 for proteins; -y, dropoff for blast extension in bits (X): default=20 for blastn / 7 for others; -X, X dropoff value for gapped alignments (bits): default=15 for all programs but not for blastn; and -Z, final X dropoff value for gapped alignments (bits): 50 for blastn, 25 for others). ClustalW for pairwise protein alignments can also be used (default parameters may include, for example, a Blosum62 matrix, and gap opening penalty=10, and gap extension penalty=0.1). Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty), with equivalent settings for protein comparisons being GAP=8 and LEN=2.

[0108] In each of the foregoing embodiments, it is contemplated herein that the immunoglobulin heavy chain variable region sequence and / or light chain variable region sequence that binds to HGF may contain amino acid modifications, e.g., at least 1, 2, 3, 4, 5, or 10 amino acid substitutions, deletions, or additions, e.g., in the framework regions of the heavy chain variable region and / or light chain variable region.

[0109] In certain embodiments, the heavy chain variable region sequence is, for example, the V H It is contemplated that the sequence or any variant thereof may be covalently linked to a variety of heavy chain constant region sequences known in the art. Similarly, a light chain variable region sequence, such as the V L It is contemplated that either variant may be covalently linked to a variety of light chain constant region sequences known in the art.

[0110] For example, the antibody molecule may have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; in particular, for example, from IgG1, IgG2, IgG3, and IgG4 (e.g., human) heavy chain constant regions. In other embodiments, the antibody molecule has a light chain constant region selected from, for example, kappa or lambda (e.g., human) light chain constant regions. The constant region may be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, number of cysteine ​​residues, effector cell function, and / or complement function). In one embodiment, the antibody has effector function and / or may fix complement. In other embodiments, the antibody does not recruit effector cells and / or fix complement. In other embodiments, the antibody has reduced or no binding ability to Fc receptors. For example, the antibody may be an isotype or subtype, fragment or other variant that does not support binding to an Fc receptor, e.g., the antibody has a mutated or deleted Fc receptor binding region.

[0111] In certain embodiments, the anti-HGF antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 17, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 17; and / or an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 18, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 18.

[0112] In certain embodiments, the antibody has a K of 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.75 nM, 0.5 nM, 0.1 nM, 0.075 nM, 0.05 nM, 0.01 nM, 0.0075 nM, 0.005 nM, 0.001 nM or less as measured using standard binding assays, e.g., surface plasmon resonance or biolayer interference. DIn certain embodiments, the antibody binds to human HGF at a binding affinity of about 20 nM to about 0.001 nM, about 20 nM to about 0.005 nM, about 20 nM to about 0.0075 nM, about 20 nM to about 0.01 nM, about 20 nM to about 0.05 nM, about 20 nM to about 0.075 nM, about 20 nM to about 0.1 nM, about 20 nM to about 0.5 nM, about 20 nM to about 1 nM, about 10 nM to about 0.001 nM, about 10 nM to about 0.005 nM, as measured using standard binding assays, such as surface plasmon resonance or biolayer interference. from about 10 nM to about 0.0075 nM, from about 10 nM to about 0.01 nM, from about 10 nM to about 0.05 nM, from about 10 nM to about 0.075 nM, from about 10 nM to about 0.1 nM, from about 10 nM to about 0.5 nM, from about 10 nM to about 1 nM, from about 5 nM to about 0.001 nM, from about 5 nM to about 0.005 nM, from about 5 nM to about 0.0075 nM, from about 5 nM to about 0.01 nM, from about 5 nM to about 0.05 nM, from about 5 nM to about 0.075 nM, from about 5 nM to about 0.1 nM, from about 5 nM to about 0.5 nM, about 5 nM to about 1 nM, about 3 nM to about 0.001 nM, about 3 nM to about 0.005 nM, about 3 nM to about 0.0075 nM, about 3 nM to about 0.01 nM, about 3 nM to about 0.05 nM, about 3 nM to about 0.075 nM, about 3 nM to about 0.1 nM, about 3 nM to about 0.5 nM, about 3 nM to about 1 nM, about 3 nM to about 2 nM, about 2 nM to about 0.001 nM, about 2 nM to about 0.005 nM, about 2 nM to about 0.0075 nM, about 2 nM to about 0.01 nM, nM to about 0.05 nM, about 2 nM to about 0.075 nM, about 2 nM to about 0.1 nM, about 2 nM to about 0.5 nM, about 2 nM to about 1 nM, about 1 nM to about 0.001 nM, about 1 nM to about 0.005 nM, about 1 nM to about 0.0075 nM, about 1 nM to about 0.01 nM, about 1 nM to about 0.05 nM, about 1 nM to about 0.075 nM, about 1 nM to about 0.1 nM, about 1 nM to about 0.5 nM, about 0.5 nM to about 0.001 nM, about 0.5 nM to about 0.005 nM, about 0.5 nM to about 0.0075 nM, about 0.5 nM to about 0.01 nM, about 0.5 nM to about 0.05 nM, about 0.5 nM to about 0.075 nM, about 0.5 nM to about 0.1 nM, about 0.1 nM to about 0.001 nM, about 0.1 nM to about 0.005 nM, about 0.1 nM to about 0.0075 nM, about 0.1 nM to about 0.01 nM, K of about 0.1 nM to about 0.05 nM, about 0.1 nM to about 0.075 nM, about 0.075 nM to about 0.001 nM, about 0.075 nM to about 0.005 nM, about 0.075 nM to about 0.0075 nM, about 0.075 nM to about 0.01 nM, about 0.075 nM to about 0.05 nM, or about 0.05 nM to about 0.035 nM. D and binds to human HGF.

[0113] In certain embodiments, the invention provides antibodies that bind to the same epitope present in HGF as the disclosed antibodies. In certain embodiments, the invention provides antibodies that compete with the disclosed antibodies for binding to HGF.

[0114] Competitive assays for determining whether an antibody binds to the same epitope as a disclosed antibody or competes with a disclosed antibody for binding are known in the art. Exemplary competitive assays include immunoassays (e.g., ELISA assays, RIA assays), surface plasmon resonance (e.g., BIAcore analysis), biolayer interference, and flow cytometry.

[0115] Typically, a competitive assay involves the use of an antigen (e.g., human HGF protein or fragment thereof) bound to a solid surface or expressed on a cell surface, an HGF-binding test antibody, and a reference antibody. The reference antibody is labeled and the test antibody is unlabeled. Competitive inhibition is measured by determining the amount of labeled reference antibody bound to the solid surface or cells in the presence of the test antibody. Typically, the test antibody is present in excess (e.g., 1x, 5x, 10x, 20x, or 100x). Antibodies identified by competitive assays (i.e., competing antibodies) include antibodies that bind to the same epitope as the reference antibody, or to a similar (e.g., overlapping) epitope, and antibodies that bind to an adjacent epitope sufficiently close to the epitope bound by the reference antibody such that steric hindrance occurs.

[0116] Competitive assays can be performed in both orientations to ensure that the presence of label does not interfere with or inhibit binding, e.g., in one orientation, the reference antibody is labeled and the test antibody is unlabeled, and in a second orientation, the test antibody is labeled and the reference antibody is unlabeled.

[0117] A test antibody competes with a reference antibody for specific binding to an antigen if an excess of one antibody (e.g., 1x, 5x, 10x, 20x or 100x) inhibits binding of the other antibody by, e.g., at least 50%, 75%, 90%, 95% or 99%, as measured in a competitive binding assay.

[0118] Two antibodies can be determined to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody. Two antibodies can be determined to bind overlapping epitopes if only a subset of amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody.

[0119] In certain embodiments, the antibody (i) comprises an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:7, and an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:8, and (ii) competes with and / or binds to the same epitope on human HGF as an antibody comprising an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7, and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:8, for binding to human HGF.

[0120] Additional anti-HGF antibodies are described in International (PCT) Patent Application Publication No. 2007 / 143098, the contents of which are incorporated by reference in their entirety.

[0121] The antibodies disclosed herein may be further optimized (e.g., affinity matured) to improve biochemical characteristics, including affinity and / or specificity, to improve biophysical properties, including aggregation, stability, precipitation, and / or non-specific interactions, and / or to reduce immunogenicity. Affinity maturation methods are within the skill of the art. For example, diversity may be introduced into the immunoglobulin heavy and / or immunoglobulin light chains by DNA shuffling, chain shuffling, CDR shuffling, random mutagenesis, and / or site-directed mutagenesis.

[0122] In certain embodiments, the isolated human antibody contains one or more somatic mutations, in which case the antibody can be modified to human germline sequences (i.e., a process called germlining) to optimize the antibody.

[0123] Generally, an optimized antibody has at least the same, or substantially the same, affinity for an antigen as the non-optimized (or parent) antibody from which it was derived. Preferably, an optimized antibody has a higher affinity for an antigen than the parent antibody.

[0124] In certain embodiments, the disclosed antibodies can be conjugated to an effector agent, such as a small molecule toxin or radionuclide, using standard in vitro conjugation chemistry. Where the effector agent is a polypeptide, the antibody can be chemically conjugated to the effector or linked to the effector as a fusion protein. Construction of fusion proteins is within the skill of one of ordinary skill in the art.

[0125] In a particular embodiment, the anti-HGF antibody is ficlatuzumab (AV-299). Ficlatuzumab is a humanized HGF inhibitory immunoglobulin G1 (IgG1) monoclonal antibody. CDRs of ficlatuzumab H1 , CDR H2 , and CDR H3 The amino acid sequences of the sequences are shown in SEQ ID NOs: 1, 2 and 3, respectively. L1 , CDR L2 , and CDR L3 The amino acid sequences of the sequences are set forth in SEQ ID NOs: 4, 5, and 6, respectively. The amino acid sequence of the heavy chain variable region of ficlatuzumab is set forth in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region of ficlatuzumab is set forth in SEQ ID NO: 8. The amino acid sequence of the heavy chain of ficlatuzumab is set forth in SEQ ID NO: 17, and the amino acid sequence of the light chain is set forth in SEQ ID NO: 18.

[0126] In certain embodiments, the anti-HGF antibody is rilotumumab. H1 , CDR H2 , and CDR H3 The amino acid sequences of the sequences are shown in SEQ ID NOs: 21, 22 and 23, respectively. L1 , CDR L2 , and CDR L3 The amino acid sequences of the sequences are set forth in SEQ ID NOs: 24, 25, and 26, respectively. The amino acid sequence of the heavy chain variable region of rilotumumab is set forth in SEQ ID NO: 27, and the amino acid sequence of the light chain variable region of rilotumumab is set forth in SEQ ID NO: 28. The amino acid sequence of the heavy chain of rilotumumab is set forth in SEQ ID NO: 29, and the amino acid sequence of the light chain is set forth in SEQ ID NO: 30.

[0127] III. EGFR Inhibitors 1) Epidermal growth factor receptor in cancer EGFR is a member of the ErbB / HER family of transmembrane glycoprotein receptor tyrosine kinases (RTKs). Activated EGFR initiates a multifaceted network of downstream signaling cascades that include cell proliferation, invasion, angiogenesis, and metastasis, triggered by Ras / Raf / MAPK, PI3K / Akt, STAT, and Src kinases (Ciardiello, F. et al., European Journal of Cancer (2003) 39:1348-1354).

[0128] Forced overexpression of EGFR in vitro causes malignant transformation of oral epithelial cells, suggesting its role as an oncogene in HNSCC. EGFR overexpression, as measured by immunohistochemistry (IHC), and increased EGFR gene copy number, as measured by fluorescent in situ hybridization, occur in the majority of HNSCC and are associated with increased stage and reduced recurrence-free and overall survival (OS) (Chung, CH, et al., J Clin Oncol. (2006) 24:4170-4176; Grandis, JR, et al., Cancer (1996) 78:1284-1292; Dassonville, O., et al., Journal of Clinical Oncology (1993) 11:1873-1878; Chung, CH, et al., Int J Radiat Oncol Biol Phys. (2011) 81:331-338).

[0129] 2) EGFR inhibitors It is contemplated that various EGFR inhibitors can be used in the practice of the present invention. The inhibitor can completely or partially inhibit or reduce a given EGFR activity or a given EGFR-mediated activity compared to an untreated control sample (e.g., tissue or body fluid sample) or subject. For example, a particular EGFR inhibitor can act by blocking, reducing, or neutralizing the binding between EGFR and an EGFR ligand (e.g., EGF). It is understood that an EGFR inhibitor can block, reduce, or neutralize the binding between EGFR and an EGFR ligand by directly or indirectly binding to EGFR, or alternatively by directly or indirectly binding to an EGFR ligand (e.g., EGF). Alternatively or additionally, the EGFR inhibitor can act by reducing the expression of EGFR or an EGFR ligand (e.g., EGF). Alternatively or additionally, the EGFR inhibitor can directly or indirectly inhibit the downstream effect of the interaction between EGFR and an EGFR ligand (e.g., EGF).

[0130] Exemplary EGFR inhibitors include antibodies, nucleic acid based therapeutics, such as aptamers and spiegelmers, that bind to a target of interest such as EGFR, or antisense or siRNA molecules or CRISPR systems that inhibit expression and / or activity of a target of interest such as EGFR, or small molecule inhibitors, such as small molecule inhibitors of EGFR, or combinations thereof.

[0131] It is understood that in certain embodiments, different EGFR inhibitors may be administered in combination.

[0132] 3) Anti-EGFR antibody In certain embodiments, the EGFR inhibitor is an anti-EGFR antibody or an antigen-binding fragment thereof.

[0133] In certain embodiments, the anti-EGFR antibody comprises a CDR comprising the amino acid sequence of SEQ ID NO:9. H1 , CDR comprising the amino acid sequence of SEQ ID NO: 10 H2 and a CDR comprising the amino acid sequence of SEQ ID NO:11.H3 An immunoglobulin heavy chain variable region including the CDR H1 , CDR H2 , and CDR H3 the sequence is interposed between the immunoglobulin FR sequences; and / or the CDR comprises the amino acid sequence of SEQ ID NO: 12. L1 , CDR comprising the amino acid sequence of SEQ ID NO: 13 L2 and a CDR comprising the amino acid sequence of SEQ ID NO: 14. L3 An immunoglobulin light chain variable region including the CDR L1 , CDR L2 , and CDR L3 The sequences may include intervening immunoglobulin FR sequences.

[0134] In certain embodiments, the anti-EGFR antibody comprises a CDR comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:9. H1 CDRs comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 10. H2 and a CDR comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO:11. H3 An immunoglobulin heavy chain variable region including the CDR H1 , CDR H2 , and CDR H3 the CDR sequence is interposed between the immunoglobulin FR sequences; and / or the CDR comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 12. L1 , a CDR comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 13 L2 and a CDR comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of SEQ ID NO: 14.L3 An immunoglobulin light chain variable region including the CDR L1 , CDR L2 , and CDR L3 The sequences may include intervening immunoglobulin FR sequences.

[0135] In certain embodiments, the anti-EGFR antibody comprises an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:15, and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:16.

[0136] In certain embodiments, an anti-EGFR antibody comprises an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the entire variable region and / or framework region sequence of the amino acid sequence of SEQ ID NO: 15. In certain embodiments, an anti-HGF antibody comprises an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the entire variable region and / or framework region sequence of the amino acid sequence of SEQ ID NO: 16.

[0137] In each of the foregoing embodiments, it is contemplated herein that the immunoglobulin heavy and / or light chain variable region sequences that bind to EGFR can contain amino acid modifications, e.g., at least 1, 2, 3, 4, 5, or 10 amino acid substitutions, deletions, or additions, e.g., in the framework regions of the heavy and / or light chain variable regions.

[0138] In certain embodiments, the heavy chain variable region sequence is, for example, the V H It is contemplated that the sequence or any variant thereof may be covalently linked to various heavy chain constant regions known in the art. Similarly, the light chain variable region sequence, e.g., V of SEQ ID NO: 16, L It is contemplated that either variant may be covalently linked to a variety of light chain constant region sequences known in the art.

[0139] For example, the antibody molecule may have a heavy chain constant region selected from, for example, IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE; in particular, for example, from IgG1, IgG2, IgG3, and IgG4 (e.g., human) heavy chain constant regions. In other embodiments, the antibody molecule has a light chain constant region selected from, for example, kappa or lambda (e.g., human) light chain constant regions. The constant region may be altered, e.g., mutated, to modify the properties of the antibody (e.g., to increase or decrease one or more of Fc receptor binding, antibody glycosylation, number of cysteine ​​residues, effector cell function, and / or complement function). In one embodiment, the antibody has effector function and / or may fix complement. In other embodiments, the antibody does not recruit effector cells and / or fix complement. In other embodiments, the antibody has reduced or no binding ability to Fc receptors. For example, the antibody may be an isotype or subtype, fragment or other variant that does not support binding to an Fc receptor, e.g., the antibody has a mutated or deleted Fc receptor binding region.

[0140] In certain embodiments, the anti-EGFR antibody comprises an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 19, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 19; and / or an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence having at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 20.

[0141] In certain embodiments, the antibody has a K of 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.75 nM, 0.5 nM, 0.1 nM, 0.075 nM, or 0.05 nM or less as measured using standard binding assays, e.g., surface plasmon resonance or biolayer interference. DIn certain embodiments, the antibody binds to human EGFR at a binding affinity of about 20 nM to about 0.05 nM, about 20 nM to about 0.075 nM, about 20 nM to about 0.1 nM, about 20 nM to about 0.5 nM, about 20 nM to about 1 nM, about 10 nM to about 0.05 nM, about 10 nM to about 0 nM, or about 10 nM to about 0 nM, as measured using standard binding assays, such as surface plasmon resonance or biolayer interference. .075 nM, about 10 nM to about 0.1 nM, about 10 nM to about 0.5 nM, about 10 nM to about 1 nM, about 5 nM to about 0.05 nM, about 5 nM to about 0.075 nM, about 5 nM to about 0.1 nM, about 5 nM to about 0.5 nM, about 5 nM to about 1 nM, about 3 nM to about 0.05 nM, about 3 nM to about 0.075 nM, 3 nM to about 0.1 nM, about 3 nM to about 0.5 nM, about 3 nM to about 1 nM, about 3 nM to about 2 nM, about 2 nM to about 0.05 nM, about 2 nM to about 0.075 nM, about 2 nM to about 0.1 nM, about 2 nM to about 0.5 nM, about 2 nM to about 1 nM, about 1 nM to about 0.05 nM, about 1 nM to about 0.075 nM, about K of 1 nM to about 0.1 nM, about 1 nM to about 0.5 nM, about 0.5 nM to about 0.05 nM, about 0.5 nM to about 0.075 nM, about 0.5 nM to about 0.1 nM, about 0.1 nM to about 0.05 nM, about 0.1 nM to about 0.075 nM, or about 0.075 nM to about 0.05 nM, or about 0.05 nM to about 0.035 nM D and binds to human EGFR.

[0142] In certain embodiments, the invention provides antibodies that bind to the same epitope present in EGFR as the disclosed antibodies. In certain embodiments, the invention provides antibodies that compete with the disclosed antibodies for binding to EGFR.

[0143] In certain embodiments, the antibody (i) comprises an immunoglobulin heavy chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 15, and an immunoglobulin light chain variable region comprising an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 16, and (ii) competes for binding to human HGF with, and / or binds to the same epitope on human EGFR as, an antibody comprising an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15, and an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 16.

[0144] The antibodies disclosed herein may be further optimized (e.g., affinity matured) to improve biochemical characteristics, including affinity and / or specificity, to improve biophysical properties, including aggregation, stability, precipitation, and / or non-specific interactions, and / or to reduce immunogenicity. Affinity maturation methods are within the skill of the art. For example, diversity may be introduced into the immunoglobulin heavy and / or immunoglobulin light chains by DNA shuffling, chain shuffling, CDR shuffling, random mutagenesis, and / or site-directed mutagenesis.

[0145] In certain embodiments, the isolated human antibody contains one or more somatic mutations, in which case the antibody can be modified to human germline sequences (i.e., a process called germlining) to optimize the antibody.

[0146] In certain embodiments, the disclosed antibodies can be conjugated to an effector agent, such as a small molecule toxin or radionuclide, using standard in vitro conjugation chemistry. Where the effector agent is a polypeptide, the antibody can be chemically conjugated to the effector or linked to the effector as a fusion protein. Construction of fusion proteins is within the skill of one of ordinary skill in the art.

[0147] In a particular embodiment, the anti-EGFR antibody is cetuximab (ERBITUX®). Cetuximab is an IgG1 mouse-human chimeric antibody against EGFR. CDRs of Cetuximab H1 , CDR H2 , and CDR H3 The amino acid sequences of the sequences are shown in SEQ ID NOs: 9, 10 and 11, respectively. CDRs of Cetuximab L1 , CDR L2 , and CDR L3 The amino acid sequences of the sequences are set forth in SEQ ID NOs: 12, 13, and 14, respectively. The amino acid sequence of the heavy chain variable region of cetuximab is set forth in SEQ ID NO: 15, and the amino acid sequence of the light chain variable region of cetuximab is set forth in SEQ ID NO: 16. The amino acid sequence of the heavy chain of cetuximab is set forth in SEQ ID NO: 19, and the amino acid sequence of the light chain is set forth in SEQ ID NO: 20.

[0148] In a particular embodiment, the anti-EGFR antibody is imgatuzumab, the amino acid sequence of the heavy chain of imgatuzumab is set forth in SEQ ID NO:31, and the amino acid sequence of the light chain of imgatuzumab is set forth in SEQ ID NO:32.

[0149] In a particular embodiment, the anti-EGFR antibody is necitumumab, the amino acid sequence of the heavy chain of necitumumab being set forth in SEQ ID NO:33, and the amino acid sequence of the light chain being set forth in SEQ ID NO:34.

[0150] In a particular embodiment, the anti-EGFR antibody is amivantamab (an EGFR and MET bispecific antibody). The amino acid sequences of the heavy chain and light chain of amivantamab are set forth in SEQ ID NO:35 and SEQ ID NO:36, and SEQ ID NO:37 and SEQ ID NO:38, respectively.

[0151] In a particular embodiment, the anti-EGFR antibody is zalutumumab. The amino acid sequence of the heavy chain of zalutumumab is set forth in SEQ ID NO:39, and the amino acid sequence of the light chain is set forth in SEQ ID NO:40.

[0152] In a particular embodiment, the anti-EGFR antibody is panitumumab, the amino acid sequence of the heavy chain of panitumumab being set forth in SEQ ID NO:41, and the amino acid sequence of the light chain being set forth in SEQ ID NO:42.

[0153] In a particular embodiment, the anti-EGFR antibody is nimotuzumab, the amino acid sequence of the heavy chain of nimotuzumab is set forth in SEQ ID NO: 43, and the amino acid sequence of the light chain of nimotuzumab is set forth in SEQ ID NO: 44.

[0154] In a particular embodiment, the anti-EGFR antibody is matuzumab, the amino acid sequence of the heavy chain of matuzumab is set forth in SEQ ID NO:45, and the amino acid sequence of the light chain of matuzumab is set forth in SEQ ID NO:46.

[0155] IV. Pharmaceutical Compositions The HGF and / or EGFR inhibitor is preferably combined with a pharma- ceutically acceptable carrier.

[0156] Pharmaceutically acceptable carriers include any of the standard pharmaceutical carriers, such as phosphate buffered saline solutions, water, emulsions (e.g., oil / water emulsions or water / oil emulsions), and various types of wetting agents. The compositions may also include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Edition, Mack Publ. Co., Easton, PA

[1975] . Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic agents, and absorption delaying agents, etc., that are compatible with pharmaceutical administration. The use of such media and agents with pharmaceutical active substances is well known in the art.

[0157] In certain embodiments, a pharmaceutical composition may contain formulation materials to modify, maintain, or preserve, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, absorption or permeation of the composition.In such embodiments, suitable formulation materials include amino acids (e.g., glycine, glutamine, asparagine, arginine, or lysine); antimicrobial agents; antioxidants (e.g., ascorbic acid, sodium sulfite, or sodium bisulfite, etc.); buffers (e.g., borate, bicarbonate, Tris-HCl, citrate, phosphate, or other organic acids, etc.); bulking agents (e.g., mannitol or glycine, etc.); chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA), etc.); complexing agents (e.g., caffeine, polyvinylpyrrolidone, beta cyclodextrin, or hydroxypropyl beta cyclodextrin, etc.); fillers; monosaccharides; disaccharides; and other carbohydrates (e.g., glucose, mannose, or dextrin, etc.); proteins (e.g., serum albumin, gelatin, or immunoglobulins, etc.); colorants, flavoring agents, and diluents; emulsifiers; hydrophilic polymers (e.g., polyvinylpyrrolidone, etc.); low molecular weight polypeptides; salt-forming counterions. (e.g., sodium and the like); preservatives (e.g., benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide, and the like); solvents (e.g., glycerin, propylene glycol, or polyethylene glycol); sugar alcohols (e.g., mannitol or sorbitol, and the like); suspending agents; surfactants or wetting agents (e.g., pluronic, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tyloxapol, and the like); stability enhancers (e.g., sucrose or sorbitol, and the like); tonicity enhancers (e.g., alkali metal halides, preferably sodium chloride, or potassium chloride, mannitol sorbitol, and the like); delivery vehicles; diluents; excipients and / or pharmaceutical adjuvants (see Remington's Pharmaceutical Sciences, 18th Edition (Mack Publishing Company, 1990).

[0158] The pharmaceutical compositions containing the HGF and / or EGFR inhibitors disclosed herein may be presented in unit dosage form and may be prepared by any suitable method. The pharmaceutical composition should be formulated to be compatible with its intended route of administration. Examples of routes of administration are intravenous (IV), intradermal, inhalation, transdermal, topical, transmucosal, intrathecal, and rectal administration. In one embodiment, the HGF inhibitor, e.g., ficlatuzumab, and the EGFR inhibitor, e.g., cetuximab, are administered by intravenous infusion. The compositions described herein may be administered locally or systemically. Administration is generally parenteral. Preparations for parenteral administration include sterile, aqueous or non-aqueous solutions, suspensions, and emulsions. Suitable formulation components for parenteral administration include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates, or phosphates; and tonicity adjusters such as sodium chloride or glucose.

[0159] In certain embodiments, the HGF and / or EGFR inhibitors disclosed herein are administered by IV infusion.For IV administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS).The carrier is stable under the conditions of manufacture and storage and is protected from microorganisms.The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.

[0160] Pharmaceutical preparations are preferably sterile.Sterilization can be achieved by any suitable method, for example, filtration through a sterile filtration membrane.In certain embodiments, HGF and / or EGFR inhibitor is lyophilized and then reconstituted in buffered saline at the time of administration.When the composition is lyophilized, it can be sterilized by filtration before or after lyophilization and reconstitution.

[0161] V. Treatment Method The present invention includes methods of treating cancer with HGF inhibitors and EGFR inhibitors. In some embodiments, the present invention includes treatment of recurrent or metastatic HNSCC with ficlatuzumab and cetuximab. In some embodiments, the present invention includes treatment of immune checkpoint inhibitor-resistant recurrent or metastatic HNSCC with ficlatuzumab and cetuximab. In some embodiments, the present invention includes treatment of platinum-resistant recurrent or metastatic HNSCC with ficlatuzumab and cetuximab. In some embodiments, the present invention includes treatment of immune checkpoint inhibitor-resistant and platinum-resistant recurrent or metastatic HNSCC with ficlatuzumab and cetuximab. In some embodiments, immune checkpoint inhibitors may include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, TIM-3 inhibitors, LAG-3 inhibitors, TIGIT inhibitors, VISTA inhibitors, KIR inhibitors, 2B4 inhibitors, CD160 inhibitors, CGEN-15049 inhibitors, CHK1 inhibitors, CHK2 inhibitors, A2aR inhibitors, or any combination thereof. In some embodiments, PD-1 inhibitors may include nivolumab, pembrolizumab, pidilizumab, REGN2810, PDR001, or any combination thereof. In some embodiments, PD-L1 inhibitors may include durvalumab, atezolizumab, avelumab, or any combination thereof. In some embodiments, CTLA-4 inhibitors may include ipilimumab, tremelimumab, AGEN-1884, or any combination thereof. In some embodiments, the TIM-3 inhibitor may include TSR-022, LY3321367, MBG453, or any combination thereof. In some embodiments, the TIGIT inhibitor may include BMS-986207, AGEN17, tiragolumab, MK-7684, OMP-313M32, EOS-448, AB154, or a combination thereof. In some embodiments, the LAG-3 inhibitor may include BMS-986016, REGN3767, IMP321, LAG525, BI754111, favezelimab, or a combination thereof.In some embodiments, VISTA inhibitors may include CI-8993, HMBD-002, PSGL-1 antagonists described in WO2018 / 132476, or combinations thereof.

[0162] In some embodiments, the present invention includes the treatment of recurrent or metastatic HNSCC with ficlatuzumab, cetuximab, and immune checkpoint inhibitors. In some embodiments, ficlatuzumab and cetuximab are added to a treatment regimen that already includes an immune checkpoint inhibitor to improve clinical benefit. In some embodiments, the immune checkpoint inhibitor may include a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a VISTA inhibitor, a KIR inhibitor, a 2B4 inhibitor, a CD160 inhibitor, a CGEN-15049 inhibitor, a CHK1 inhibitor, a CHK2 inhibitor, an A2aR inhibitor, or any combination thereof. In some embodiments, the PD-1 inhibitor may include nivolumab, pembrolizumab, pidilizumab, REGN2810, PDR001, or any combination thereof. In some embodiments, the PD-L1 inhibitor may include durvalumab, atezolizumab, avelumab, or any combination thereof. In some embodiments, the CTLA-4 inhibitor may include ipilimumab, tremelimumab, AGEN-1884, or any combination thereof. In some embodiments, the TIM-3 inhibitor may include TSR-022, LY3321367, MBG453, or any combination thereof. In some embodiments, the TIGIT inhibitor may include BMS-986207, AGEN17, tiragolumab, MK-7684, OMP-313M32, EOS-448, AB154, or any combination thereof. In some embodiments, the LAG-3 inhibitor may include BMS-986016, REGN3767, IMP321, LAG525, BI754111, favezelimab, or any combination thereof. In some embodiments, the VISTA inhibitor may include CI-8993, HMBD-002, PSGL-1 antagonists described in WO2018 / 132476, or combinations thereof. In some embodiments, the platinum is carboplatin, oxaliplatin, cisplatin, nedaplatin, triplatin tetranitrate, lobaplatin, phenanthriplatin, picoplatin, and satraplatin.

[0163] The methods and compositions of the present invention can be used to treat any type of cancer, including but not limited to lung cancer, liver cancer, ovarian cancer, prostate cancer, testicular cancer, gallbladder cancer, sarcoma, Ewing's sarcoma, thyroid cancer, melanoma, skin cancer, pancreatic cancer; gastrointestinal / gastric (GIST (gastrointestinal stromal tumor)) cancer, lymphoma, head and neck cancer, glioma, or brain cancer, colon cancer, rectal cancer, colorectal cancer, breast cancer, renal cell carcinoma, or kidney cancer. In one embodiment, the cancer is head and neck squamous cell carcinoma (HNSCC). In some embodiments, the HNSCC is hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, nasopharyngeal cancer, oropharynx cancer, paranasal sinus cancer and / or nasal cavity cancer, or salivary gland cancer. In some embodiments, the cancer is colon cancer, rectal cancer, and / or colorectal cancer. In some embodiments, the cancer is HPV-negative cancer. In some embodiments, the cancer is colon cancer, rectal cancer, and / or colorectal cancer treated with cetuximab and ficlatuzumab according to the methods disclosed herein. In some embodiments, the cancer is HPV-negative cancer treated with cetuximab and ficlatuzumab according to the invention disclosed herein. In some embodiments, the cancer is HPV-negative rectal cancer, colon cancer, or colorectal cancer treated with cetuximab and ficlatuzumab according to the invention disclosed herein.

[0164] In certain embodiments, the cancer, tumor, disease, or subject treated by the method or composition of the present invention is resistant to one or more immune checkpoint inhibitor therapies. In some embodiments, immune checkpoint inhibitor resistance refers to a subject with HNSCC that does not respond to immune checkpoint inhibitor treatment or has responded and then stopped responding. In certain embodiments, immune checkpoint inhibitor resistance refers to (i) disease persistence or recurrence within 6 months of completion of definitive radiation therapy, including concurrent immune checkpoint inhibitor therapy, for locally advanced disease, e.g., HNSCC, or (ii) disease progression during or within 6 months of immune checkpoint inhibitor treatment in a recurrent / metastatic setting, e.g., recurrent / metastatic HNSCC. In some embodiments, exposure to prior immune checkpoint inhibitor therapy can occur in any line of therapy (first line, second line, etc.), and the immune checkpoint inhibitor therapy does not have to be the most recent therapy received in order for a cancer or tumor to be classified as immune checkpoint inhibitor therapy resistant. In certain embodiments, the cancer, tumor, disease, e.g., HNSCC, or subject, e.g., a subject with HNSCC, treated by the method or composition of the present invention is immune checkpoint inhibitor therapy ineligible, i.e., is not an acceptable candidate for treatment with immune checkpoint inhibitor therapy, e.g., due to medical comorbidities. In some embodiments, the immune checkpoint inhibitor may include a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a TIM-3 inhibitor, a LAG-3 inhibitor, a TIGIT inhibitor, a VISTA inhibitor, a KIR inhibitor, a 2B4 inhibitor, a CD160 inhibitor, a CGEN-15049 inhibitor, a CHK1 inhibitor, a CHK2 inhibitor, an A2aR inhibitor, or any combination thereof. In some embodiments, the PD-1 inhibitor may include nivolumab, pembrolizumab, pidilizumab, REGN2810, PDR001, or any combination thereof. In some embodiments, PD-L1 inhibitors may include durvalumab, atezolizumab, avelumab, or any combination thereof. In some embodiments, CTLA-4 inhibitors may include ipilimumab, tremelimumab, AGEN-1884, or any combination thereof.In some embodiments, the TIM-3 inhibitor may include TSR-022, LY3321367, MBG453, or any combination thereof. In some embodiments, the TIGIT inhibitor may include BMS-986207, AGEN17, tiragolumab, MK-7684, OMP-313M32, EOS-448, AB154, or a combination thereof. In some embodiments, the LAG-3 inhibitor may include BMS-986016, REGN3767, IMP321, LAG525, BI754111, favezelimab, or a combination thereof. In some embodiments, the VISTA inhibitor may include CI-8993, HMBD-002, a PSGL-1 antagonist described in WO2018 / 132476, or a combination thereof.

[0165] In certain embodiments, the cancer, tumor, disease, or subject treated by the method or composition of the present invention is platinum-resistant. In certain embodiments, platinum resistance refers to (i) disease persistence or recurrence within 6 months of completion of definitive radiotherapy for locally advanced disease, e.g., HNSCC, where platinum chemotherapy was administered as a component of induction and / or concurrent systemic treatment, or (ii) disease progression during or within 6 months of treatment with platinum chemotherapy in a recurrent / metastatic setting, e.g., recurrent / metastatic HNSCC. In some embodiments, the prior platinum exposure can be in any line of therapy (first-line, second-line, etc.) and does not have to be the most recent therapy received for a cancer or tumor to be classified as platinum-resistant. In certain embodiments, the cancer, tumor, disease, e.g., HNSCC, or subject, e.g., a subject with HNSCC, treated by the method or composition of the present invention is platinum-ineligible, i.e., is not an acceptable candidate for platinum chemotherapy, e.g., due to medical comorbidities. Exemplary platinum chemotherapy agents include carboplatin, oxaliplatin, cisplatin, nedaplatin, triplatin tetranitrate, lobaplatin, phenanthriplatin, picoplatin, and satraplatin.

[0166] In certain embodiments, the cancer, tumor, disease, or subject treated by the method or composition of the present invention is cetuximab-resistant. In some embodiments, cetuximab-resistant refers to subjects with HNSCC who do not respond to cetuximab treatment or who responded and then stopped responding. In certain embodiments, cetuximab-resistant refers to (i) disease persistence or recurrence within 6 months of completion of definitive radiotherapy with concomitant cetuximab for locally advanced disease, e.g., HNSCC, or (ii) disease progression during or within 6 months of cetuximab treatment in a recurrent / metastatic setting, e.g., recurrent / metastatic HNSCC. In some embodiments, the prior cetuximab exposure can be in any line of therapy (curative or curative intent treatment, or first-line, second-line, etc.), and cetuximab does not have to be the most recent therapy received for a cancer or tumor to be classified as cetuximab-resistant. In certain embodiments, the cancer, tumor, disease, e.g., HNSCC, or subject, e.g., a subject with HNSCC, treated by the methods or compositions of the invention is cetuximab-ineligible, i.e., is not an acceptable candidate for treatment with cetuximab, e.g., due to medical comorbidities. In certain embodiments, cetuximab-resistant HNSCC, e.g., recurrent / metastatic HNSCC, is treated by the methods of the invention with cetuximab in combination with ficlatuzumab.

[0167] In certain embodiments, the cancer, tumor, disease, or subject treated by the method or composition of the present invention is human papillomavirus (HPV) negative. In certain embodiments, HPV positive refers to a cancer, tumor, or disease, such as HNSCC, that is p16 positive as measured by immunohistochemistry, meaning that ≧70% of the cancer, tumor, or disease cells show diffuse nuclear and cytoplasmic staining with p16 antibody. In certain embodiments, HPV negative refers to a cancer, tumor, or disease, such as HNSCC, that is not p16 positive as measured by immunohistochemistry, meaning that <70% of the cancer, tumor, or disease cells show diffuse nuclear and cytoplasmic staining with p16 antibody. In certain embodiments, HPV positive refers to an HNSCC that (i) has an oropharynx or unknown primary site, and (ii) is p16 positive, meaning that ≧70% of the cancer, tumor, or disease cells show diffuse nuclear and cytoplasmic staining with p16 antibody as measured by immunohistochemistry. In certain embodiments, HPV negative refers to HNSCC that (i) is of oropharynx or unknown primary site and is not p16 positive, meaning that <70% of the cancer, tumor, or disease cells show diffuse nuclear and cytoplasmic staining with p16 antibody, as measured by immunohistochemistry. In certain embodiments, HPV negative refers to HNSCC that is not of oropharynx or unknown primary site (i.e., HNSCC with known primary site other than oropharynx is presumed to be HPV negative). For example, HNSCC with primary site of oral cavity, larynx, and hypopharynx is presumed to be HPV negative. In some embodiments, HNSCC is HPV negative if <70% of the cancer, tumor, or disease cells are not p16 positive, meaning that <70% of the cancer, tumor, or disease cells show diffuse nuclear and cytoplasmic staining with p16 antibody, as measured by immunohistochemistry. In certain embodiments, the HPV status of the cancer, tumor, disease, or subject is evaluated prior to treatment with the methods or compositions of the present invention. Any known immunohistochemistry method can be used to identify the HPV status of a subject according to the present disclosure. For example, p16 immunohistochemical staining with a p16 antibody can be used to assess HPV status, or analysis of tumor DNA can be used to determine HPV status.Methods for determining the HPV status of HNSCC are known in the art and can be used to determine HPV status according to the present invention, see, e.g., Jordan et al., Am J Surg Pathol. (2012) 36(7):945-954.

[0168] In certain embodiments, the cancer, tumor, disease, or subject treated by the methods or compositions of the present invention is human papillomavirus (HPV) negative. In certain embodiments, HPV positive refers to a cancer, tumor, or disease in which the presence of HPV is detected by the presence of HPV nucleic acid (e.g., DNA or RNA) in the tumor of the subject, e.g., in the HNSCC of the subject. In certain embodiments, HPV negative refers to a cancer, tumor, or disease in which HPV nucleic acid (e.g., DNA or RNA) is not detected in the tumor, e.g., in the HNSCC of the subject. In certain embodiments, HPV-negative HNSCC refers to an HNSCC that (i) does not have an oropharynx or unknown primary site (i.e., HNSCC with a known primary site other than the oropharynx is presumed to be HPV negative), and / or (ii) in which HPV nucleic acid (e.g., DNA or RNA) is not detected in the tumor, e.g., in the HNSCC of the subject. In certain embodiments, the HPV status of the cancer, tumor, disease, or subject is assessed prior to treatment with the methods or compositions of the present invention. Any known method for assessing the presence or absence of HPV nucleic acid (e.g., DNA, RNA, etc.) in a subject can be used to identify a subject's HPV status according to the present disclosure (e.g., PCR, in situ hybridization, etc.). See, e.g., Jordan et al., Am J Surg Pathol. (2012) 36(7):945-954.

[0169] In one embodiment, subjects (e.g., HPV-negative subjects) treated with an HGF inhibitor and an EGFR inhibitor, such as ficlatuzumab and cetuximab, according to the methods of the present invention have an overall response rate (ORR) of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In certain embodiments, the overall response rate (ORR) is at least 35%.

[0170] In one embodiment, a subject (e.g., an HPV-negative subject) treated with an HGF inhibitor and an EGFR inhibitor, e.g., ficlatuzumab and cetuximab, according to the methods of the invention, maintains a survival time of at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 19 months, at least 20 months, at least 21 months, at least 22 months, at least 23 months, at least 24 months, at least 25 months, at least 26 months, at least 27 months, at least A median overall survival (OS) rate of 28 months, at least 29 months, at least 30 months, at least 31 months, at least 32 months, at least 33 months, at least 34 months, at least 35 months, at least 36 months, at least 37 months, at least 38 months, at least 39 months, at least 40 months, at least 41 months, at least 42 months, at least 43 months, at least 44 months, at least 45 months, at least 46 months, at least 47 months, at least 48 months, at least 49 months, at least 50 months, at least 51 months, at least 52 months, at least 53 months, at least 54 months, at least 55 months, at least 56 months, at least 57 months, at least 58 months, at least 59 months, or at least 60 months.

[0171] In certain embodiments, a subject (e.g., an HPV-negative subject) treated with an HGF inhibitor and an EGFR inhibitor, e.g., ficlatuzumab and cetuximab, according to the methods of the invention, has a gestational age of about 60 months to about 1 month, about 60 months to about 2 months, about 60 months to about 3 months, about 60 months to about 4 months, about 60 months to about 5 months, about 60 months to about 6 months, about 60 months to about 7 months, about 60 months to about Up to 8 months, From about 60 months to about 9 months, From about 60 months to about 10 months, From about 60 months to about 20 months, From about 30 months to about 1 month, From about 30 months to about 2 months, From about 30 months to about 3 months, From about 30 months to about 4 months, From about 30 months to about 5 months, From about 30 months to about 6 months, From about 30 months to about 7 months, From about 30 months to about 8 months, From about 30 months to about 9 months, From about 30 months to about 1 Up to 0 months, From about 30 months to about 20 months, From about 15 months to about 1 month, From about 15 months to about 2 months, From about 15 months to about 3 months, From about 15 months to about 4 months, From about 15 months to about 5 months, From about 15 months to about 6 months, From about 15 months to about 7 months, From about 15 months to about 8 months, From about 15 months to about 9 months, From about 15 months to about 10 months, From about 10 months to about 1 month, From about 10 months to about 2 months from about 10 months to about 3 months, from about 10 months to about 4 months, from about 10 months to about 5 months, from about 10 months to about 6 months, from about 10 months to about 7 months, from about 10 months to about 8 months, from about 10 months to about 9 months, from about 6 months to about 1 month, from about 6 months to about 2 months, from about 6 months to about 3 months, from about 6 months to about 4 months, or from about 6 months to about 5 months.

[0172] In one embodiment, a subject (e.g., an HPV-negative subject) treated with an HGF inhibitor and an EGFR inhibitor, e.g., ficlatuzumab and cetuximab, according to the methods of the invention, exhibits a survival time of at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 13 months, at least 14 months, at least 15 months, at least 16 months, at least 17 months, at least 18 months, at least 19 months, at least 20 months, at least 21 months, at least 22 months, at least 23 months, at least 24 months, at least 25 months, at least 26 months, at least 27 months, at least 28 months, at least 29 months, at least 30 months, at least 31 months, at least 32 months, at least 33 months, at least 34 months, at least 35 months, at least 36 months, at least 37 months, at least 38 months, at least 39 months, at least 40 months, at least 41 months, at least 42 months, at least 43 months, at least 44 months, at least 45 months, at least 46 months, at least 47 months, at least 48 months, at least 49 months, at least 50 months, at least 51 months, at least 52 months, at least 53 months, at least 54 months, at least 55 months, at least 56 months, at least 57 months, at least 58 months, at least 59 months, at least 60 months, at least 61 months, at least 62 months, at least 63 months, at least 64 months, at least 65 months months, at least 29 months, at least 30 months, at least 31 months, at least 32 months, at least 33 months, at least 34 months, at least 35 months, at least 36 months, at least 37 months, at least 38 months, at least 39 months, at least 40 months, at least 41 months, at least 42 months, at least 43 months, at least 44 months, at least 45 months, at least 46 months, at least 47 months, at least 48 months, at least 49 months, at least 50 months, at least 51 months, at least 52 months, at least 53 months, at least 54 months, at least 55 months, at least 56 months, at least 57 months, at least 58 months, at least 59 months, or at least 60 months.

[0173] In certain embodiments, a subject (e.g., an HPV-negative subject) treated with an HGF inhibitor and an EGFR inhibitor, e.g., ficlatuzumab and cetuximab, according to the methods of the invention, is treated for about 60 months to about 1 month, about 60 months to about 2 months, about 60 months to about 3 months, about 60 months to about 4 months, about 60 months to about 5 months, about 60 months to about 6 months, about 60 months to about 7 months, about 60 months to about 8 months, about 60 months to about 9 months, about 60 months to about 10 months, about 60 months to about 12 months, about 60 months to about 14 months, about 60 months to about 16 months, about 60 months to about 18 months, about 60 months to about 19 months, about 60 months to about 20 months, about 60 months to about 21 months, about 60 months to about 22 months, about 60 months to about 24 months, about 60 months to about 26 months, about 60 months to about 28 months, about 60 months to about 29 months, about 60 months to about 30 months, about 60 months to about 31 months, about 60 months to about 32 months, about 60 months to about 33 months, about 60 months to about 34 months, about 60 months to about 35 months, about 60 months to about 36 months, about 60 months to about 37 months, about 60 months to about 38 months, about 60 months to about 39 months, about 60 months to about 40 months, about 60 months to about 40 months, about 60 months to about 40 months, about 60 months to about 50 months, about 60 months to about 50 months, about 60 months to about 50 months, about months, from about 60 months to about 9 months, from about 60 months to about 10 months, from about 60 months to about 20 months, from about 30 months to about 1 month, from about 30 months to about 2 months, from about 30 months to about 3 months, from about 30 months to about 4 months, from about 30 months to about 5 months, from about 30 months to about 6 months, from about 30 months to about 7 months, from about 30 months to about 8 months, from about 30 months to about 9 months, from about 30 months to about 10 months 30 months to 20 months, 15 months to 1 month, 15 months to 2 months, 15 months to 3 months, 15 months to 4 months, 15 months to 5 months, 15 months to 6 months, 15 months to 7 months, 15 months to 8 months, 15 months to 9 months, 15 months to 10 months, 10 months to 1 month, 10 months to 2 months and has a median progression-free survival (PFS) of about 10 months to about 3 months, about 10 months to about 4 months, about 10 months to about 5 months, about 10 months to about 6 months, about 10 months to about 7 months, about 10 months to about 8 months, about 10 months to about 9 months, about 6 months to about 1 month, about 6 months to about 2 months, about 6 months to about 3 months, about 6 months to about 4 months, or about 6 months to about 5 months. In one embodiment, the median progression-free survival (PFS) is at least 4 months.

[0174] According to certain embodiments of the invention, treatment with the HGF inhibitor and the EGFR inhibitor is indicated for as long as clinical benefit is observed in the subject or until unacceptable toxicity occurs.

[0175] Exemplary effective amounts or doses of an HGF inhibitor (e.g., an anti-HGF antibody or antigen-binding fragment thereof, e.g., ficlatuzumab) include about 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, or about 25 mg / kg. In certain embodiments, exemplary effective amounts or doses of an HGF inhibitor (e.g., an anti-HGF antibody or antigen-binding fragment thereof, e.g., ficlatuzumab) include from about 25 mg / kg to about 0.5 mg / kg, from about 25 mg / kg to about 1 mg / kg, from about 25 mg / kg to about 2 mg / kg, from about 25 mg / kg to about 3 mg / kg, from about 25 mg / kg to about 4 mg / kg, from about 25 mg / kg to about 5 mg / kg, from about 25 mg / kg to about 10 mg / kg, from about 25 mg / kg to about 15 mg / kg, from about 25 mg / kg to about 20 mg / kg, from about 20 mg / kg to about 0.5 ... The effective dose ranges from about 1 mg / kg to about 2 mg / kg, from about 20 mg / kg to about 3 mg / kg, from about 20 mg / kg to about 4 mg / kg, from about 20 mg / kg to about 5 mg / kg, from about 20 mg / kg to about 10 mg / kg, from about 20 mg / kg to about 15 mg / kg, from about 15 mg / kg to about 0.5 mg / kg, from about 15 mg / kg to about 1 mg / kg, from about 15 mg / kg to about 2 mg / kg, from about 15 mg / kg to about 3 mg / kg, from about 15 mg / kg to about 4 mg / kg, from about 15 mg / kg to about 5 mg / kg, or from about 15 mg / kg to about 10 mg / kg. In some embodiments, an exemplary effective amount or dose of an HGF inhibitor (e.g., an anti-HGF antibody or an antigen-binding fragment thereof, e.g., ficlatuzumab) is about 20 mg / kg.In some embodiments, an exemplary effective amount or dose of an HGF inhibitor (e.g., an anti-HGF antibody or an antigen-binding fragment thereof, e.g., ficlatuzumab) is about 10 mg / kg. In some embodiments, an exemplary effective amount or dose of an HGF inhibitor (e.g., an anti-HGF antibody or an antigen-binding fragment thereof, e.g., ficlatuzumab) is about 15 mg / kg.

[0176] In some embodiments, the dose of ficlatuzumab is about 20 mg / kg and the dose of cetuximab is about 500 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 15 mg / kg and the dose of cetuximab is about 500 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 10 mg / kg and the dose of cetuximab is about 500 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 20 mg / kg and the dose of cetuximab is about 400 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 15 mg / kg and the dose of cetuximab is about 400 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 10 mg / kg and the dose of cetuximab is about 400 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 20 mg / kg and the dose of cetuximab is about 300 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 15 mg / kg and the dose of cetuximab is 300 mg / m 2 In some embodiments, the dose of ficlatuzumab is about 10 mg / kg and the dose of cetuximab is 300 mg / m 2 In some embodiments, the doses of ficlatuzumab and cetuximab are given every two weeks. In some embodiments, the doses of ficlatuzumab and cetuximab are given on the same day every two weeks. In some embodiments, the doses of ficlatuzumab and cetuximab are given simultaneously or sequentially on the same day every two weeks.

[0177] An exemplary treatment regimen for an HGF inhibitor (e.g., an anti-HGF antibody or an antigen-binding fragment thereof, e.g., ficlatuzumab) includes administration of an effective dose about once a week, about once every two weeks, about once every three weeks, about once every four weeks, about once every five weeks, about once every six weeks, about once every seven weeks, or about once every eight weeks. In one embodiment, an exemplary treatment regimen for an HGF inhibitor (e.g., an anti-HGF antibody or an antigen-binding fragment thereof, e.g., ficlatuzumab) includes administration about once every one to two weeks, about once every two to three weeks, or about once every three to four weeks. In some embodiments, an exemplary treatment regimen for an HGF inhibitor (e.g., an anti-HGF antibody or an antigen-binding fragment thereof, e.g., ficlatuzumab) includes administration about once every two weeks. In some embodiments, an exemplary treatment regimen for an HGF inhibitor (e.g., an anti-HGF antibody or an antigen-binding fragment thereof, e.g., ficlatuzumab) includes administration about once every two weeks.

[0178] An exemplary effective amount or dose of an EGFR inhibitor (e.g., an anti-EGFR antibody or antigen-binding fragment thereof, e.g., cetuximab) includes about 200 mg / m 2 , about 250mg / m 2 , about 300mg / m 2 , about 400mg / m 2 , about 500mg / m 2 , about 600mg / m 2 , about 700mg / m 2 , or about 800 mg / m 2 In certain embodiments, an exemplary effective amount or dose of an EGFR inhibitor (e.g., an anti-EGFR antibody or antigen-binding fragment thereof, e.g., cetuximab) includes about 800 mg / m 2 to about 200 mg / m 2 up to about 800 mg / m 2 to about 300 mg / m 2 up to about 800 mg / m 2 to about 400 mg / m 2 up to about 800 mg / m 2 to about 500 mg / m 2 up to about 800 mg / m 2 to about 600 mg / m 2 up to about 800 mg / m 2to about 700 mg / m 2 up to about 600 mg / m 2 to about 200 mg / m 2 up to about 600 mg / m 2 to about 300 mg / m 2 up to about 600 mg / m 2 to about 400 mg / m 2 up to about 700 mg / m 2 to about 400 mg / m 2 up to about 700 mg / m 2 to about 250 mg / m 2 up to about 600 mg / m 2 to about 500 mg / m 2 up to about 500 mg / m 2 to about 300 mg / m 2 or about 300 mg / m 2 to about 200 mg / m 2 In certain embodiments, an exemplary effective amount or dose of an EGFR inhibitor (e.g., an anti-EGFR antibody or antigen-binding fragment thereof, e.g., cetuximab) is about 500 mg / m 2 It is.

[0179] An exemplary treatment regimen for an EGFR inhibitor (e.g., an anti-EGFR antibody or an antigen-binding fragment thereof, e.g., cetuximab) includes administration of an effective dose about once a week, about once every two weeks, about once every three weeks, about once every four weeks, about once every five weeks, about once every six weeks, about once every seven weeks, or about once every eight weeks. In some embodiments, an exemplary treatment regimen for an EGFR inhibitor (e.g., an anti-EGFR antibody or an antigen-binding fragment thereof, e.g., cetuximab) includes administration about once every one to two weeks, about once every two to three weeks, or about once every three to four weeks. In some embodiments, an exemplary treatment regimen for an EGFR inhibitor (e.g., an anti-EGFR antibody or an antigen-binding fragment thereof, e.g., cetuximab) is about once every two weeks. In one embodiment, an EGFR inhibitor, e.g., cetuximab, is administered on the same day as an HGF inhibitor, e.g., ficlatuzumab. For example, an EGFR inhibitor, e.g., cetuximab, is administered simultaneously with an HGF inhibitor, e.g., ficlatuzumab. In one embodiment, cetuximab and ficlatuzumab are administered on the same day every two weeks. In one embodiment, cetuximab and ficlatuzumab are administered on the same day every three weeks. In one embodiment, cetuximab and ficlatuzumab are administered on the same day every four weeks.

[0180] Dosage depends on variables such as the type and severity of the disease or indication being treated, the patient's overall health, the pharmaceutical formulation, and the route of administration. The initial dose may be increased above the upper level to rapidly achieve the desired blood or tissue level. Alternatively, the initial dose may be less than optimal, and the daily dose may be gradually increased over the course of treatment. Human doses may be optimized, for example, in conventional Phase I dose escalation studies. Dosage frequency may vary depending on factors such as the route of administration, dosage, and disease being treated. Exemplary dosing frequencies are once a day, once every other day, once every 3 days, once every 4 days, once every 5 days, once every 6 days, once a week, and once every 2 weeks.

[0181] The HGF inhibitor, e.g., ficlatuzumab, and the anti-EGFR antibody, e.g., cetuximab, can be administered simultaneously, for example, for at least one cycle of treatment. In one embodiment, the treatment cycle is 4 weeks, and includes administration of cetuximab and ficlatuzumab at week 2 and week 4. The HGF inhibitor (e.g., an anti-HGF antibody, e.g., ficlatuzumab) or the EGFR inhibitor (e.g., an anti-EGFR antibody, e.g., cetuximab) can be administered sequentially, for example, for at least one cycle of treatment. In certain embodiments, the HGF inhibitor (e.g., an anti-HGF antibody, e.g., ficlatuzumab) is administered subsequent to the EGFR inhibitor (e.g., an anti-EGFR antibody, e.g., cetuximab) for at least one cycle of treatment, e.g., the HGF inhibitor (e.g., ficlatuzumab) is administered at least 15 minutes, at least 30 minutes, at least 60 minutes, at least 120 minutes, at least 180 minutes, at least 240 minutes, or at least 300 minutes, or from about 30 minutes to about 60 minutes, after completion of administration of the EGFR inhibitor (e.g., cetuximab).

[0182] In certain embodiments discussed herein, a subject may have undergone a first-line therapy that is determined to be ineffective (e.g., due to primary resistance, acquired resistance, etc.) prior to undergoing treatment with the disclosed compositions and / or methods. A first-line therapy is a treatment that is generally accepted in the medical field for the initial treatment of a given disease or disorder (e.g., cancer). As used herein with respect to recurrent / metastatic HNSCC, first-line therapy refers to the initial treatment (i.e., initial palliative treatment) for recurrent / metastatic HNSCC, not taking into account any prior treatment (i.e., any prior curative or curative treatment) for non-recurrent or localized HNSCC. Similarly, second-line therapy for recurrent / metastatic HNSCC refers to the second treatment (i.e., second palliative treatment) for recurrent / metastatic HNSCC, not taking into account any prior treatment (i.e., any prior curative or curative treatment) for non-recurrent or localized HNSCC. In some embodiments, the first line therapy includes an antibody (e.g., a monoclonal antibody) or antibody fragment therapy, an immune checkpoint therapy, a cancer vaccine, adoptive cell transfer, a cytokine therapy, or any combination thereof. In some embodiments described herein, the first line therapy includes an immune checkpoint inhibitor therapy and / or a platinum therapy.

[0183] According to one embodiment, the subject is treated with the method of the present invention until the subject obtains clinical benefit or until the subject experiences unacceptable toxicity.For example, to treat recurrent / metastatic HNSCC, the subject is treated with cetuximab and ficlatuzumab every 2 weeks until the subject obtains clinical benefit or until the subject experiences unacceptable toxicity.For example, to treat recurrent / metastatic HNSCC, the subject is treated with cetuximab and ficlatuzumab treatment cycle (i.e., 4 weeks in which cetuximab and ficlatuzumab are administered every 2 weeks, i.e., twice during the treatment cycle), and the subject is treated with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or more treatment cycles. For example, to treat recurrent / metastatic HNSCC, subjects receive treatment cycles of cetuximab and ficlatuzumab until HNSCC progresses. EXAMPLES

[0184] The present disclosure is further illustrated by the following examples, which are provided for illustrative purposes only and are not intended to limit the disclosure in any way.

[0185] Example 1 A study investigating the efficacy of ficlatuzumab and cetuximab in the treatment of all-refractory advanced HNSCC Presented herein are exemplary protocols and exemplary results for treating subjects in need thereof with anti-HGF antibody and anti-EGFR antibody combination therapy.

[0186] A phase Ib study demonstrated safety and preliminary efficacy of cetuximab and ficlatuzumab in cetuximab-resistant advanced HNSCC (see Bauman et al., Journal of Clinical Oncology 35, No. 15 Suppl (May 20, 2017) 6038-6038; and Bauman et al., Cancers (Basel). 2020;12(6):1537, published June 11, 2020, doi:10.3390 / cancers12061537). The encouraging clinical activity observed during phase Ib in patients with cetuximab-resistant recurrent / metastatic HNSCC led to a randomized phase II study evaluating the efficacy of ficlatuzumab with or without cetuximab in patients with cetuximab-resistant recurrent / metastatic HNSCC. The recommended doses for phase II are 20 mg / kg of ficlatuzumab and 500 mg / m of cetuximab every 2 weeks. 2 (the "combination arm"), and the control arm received only ficlatuzumab at 20 mg / kg every 2 weeks. Overall response rate (ORR) and median progression-free survival (mPFS) were 17% and 5.4 months. Increases in peripheral T cells, especially the CD8+ subset, accompanied treatment response, and expansion of distinct myeloid populations accompanied progression.

[0187] 1. Study Design A. Purpose of the test The primary study objective was to evaluate the efficacy of ficlatuzumab with or without concurrent cetuximab, as measured by progression-free survival (PFS), in patients with cetuximab-resistant recurrent / metastatic HNSCC.

[0188] Secondary study objectives included describing toxicity and patient-reported quality of life, as well as assessing response rate and overall survival in both treatment arms.

[0189] b.Inclusion criteria / exclusion criteria Each patient enrolled in the study met all of the following inclusion criteria: Patients had to have histologically confirmed HNSCC from any primary site. Basaloid, poorly differentiated, and undifferentiated cancer histology were accepted. WHO types I and II (keratinizing, non-EBV positive) nasopharyngeal carcinomas were included. Sites of paranasal sinuses, lip, and external auditory canal were included. Squamous cell carcinoma of unknown primary site with apparent head and neck involvement was included. Recurrent / metastatic disease meeting at least one of the criteria defined below. Intractable diseases evaluated by surgical oncology or radiation oncology Metastatic (M1) disease Persistent or progressive disease following curative radiation and not a candidate for surgical salvage due to incurability or morbidity. Patients who declined definitive surgery were eligible. For patients with oropharyngeal or unknown primary site only, tumor HPV status established by local site was known. Acceptance criteria included p16 immunohistochemistry (tumors were classified as p16 positive if they showed diffuse nuclear and cytoplasmic staining in at least 70% of tumor cells) and / or HPV DNA assessment. Patients had to be cetuximab resistant by meeting at least one of the criteria defined below. Persistent or recurrent disease within 6 months of completion of definitive radiation therapy for locally advanced disease. Radiation had to have included concurrent cetuximab. Induction chemotherapy, if administered, could have included cetuximab or not. Disease progression during or within 6 months of cetuximab treatment in the recurrent / metastatic setting. Prior cetuximab exposure could have been in any line of therapy (first-line, second-line, etc.) and cetuximab did not have to be the most recent therapy received. Patients had to be platinum-resistant or platinum-ineligible by meeting at least one of the criteria defined below. o Persistent or recurrent disease within 6 months of completion of definitive radiotherapy for locally advanced disease in which platinum chemotherapy was administered as a component of induction and / or concurrent systemic treatment. o Disease progression during or within 6 months of treatment with platinum chemotherapy (e.g., carboplatin or cisplatin) in a recurrent / metastatic setting. * In the judgment of the local investigator, the patient was not an acceptable candidate for platinum chemotherapy due to medical comorbidities. Prior platinum exposure could have been in any line of therapy (first-line, second-line, etc.) and did not have to have been the most recent therapy received. Prior exposure to immunotherapy, including anti-PD1 / PDL1, anti-CTLA4, anti-TNFR antibodies, or other investigational immunotherapies, was permitted. Eastern Cooperative Oncology Group performance status 0-1 at the time of informed consent. Age ≥ 18 years For correlation studies, patients had to consent to a baseline tumor tissue survey biopsy. Archived biopsies were substituted only if no interval systemic anticancer therapy had been administered. Measurable disease by RECIST criteria, version 1.1 (see, e.g., Eisenhauer, EA et al., Eur J Cancer (2009) 45:228-247, paragraph 6). Patients must have had the following laboratory values ​​measured within 28 days of enrollment: Absolute neutrophil count (ANC) ≥ 1500 / mm 3 〇Platelet count (PLT)≧75,000 / mm 3 Determined by 24-hour sampling or Cockcroft-Gault method: Filled square Creatinine clearance calculation = Estimated by [(140-age) x (current weight in kg) x (0.85 (if female))] / (72 x serum creatinine) Creatinine clearance ≥ 40ml / min Serum bilirubin ≦ 1.5 times the upper limit of normal (ULN) * AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≦3 times ULN No prior severe infusion reactions to cetuximab or monoclonal antibodies Written informed consent was obtained from all patients before the start of therapy. Patients must have been able to understand and willing to sign a written informed consent document. Women of childbearing potential were required to have documented a negative pregnancy test within 14 days prior to enrollment. A negative pregnancy test was confirmed within 3 days of the first dose of ficlatuzumab. Sexually active women of childbearing potential agreed to use adequate contraception during the study and for 30 days after the last dose of study drug.

[0190] Patients who met any of the following exclusion criteria were not enrolled in the study. · Nasopharyngeal primary site (if WHO type III (non-keratinizing and EBV positive established at a local site)). History of severe allergic or anaphylactic reaction or hypersensitivity to the recombinant protein or excipients in the investigational product. Prior treatment with an HGF / cMet inhibitor, e.g., rilotumumab, crizotinib, MetMAb, or ARQ197. Uncontrolled central nervous system (CNS) metastases, including leptomeningeal metastases, were not allowed. Subjects with previously treated brain metastases were allowed if their brain metastases were stable for at least 2 weeks without steroid treatment (radiotherapy or surgery). Failure to recover to Grade 1 or baseline from all toxic effects of prior chemotherapy, radiation therapy, biologic therapy, immunotherapy, and / or experimental therapy. Exceptions: alopecia, Grade ≤ 2 peripheral neuropathy, Grade ≤ 2 cetuximab-related rash or other skin changes, hypomagnesemia (allowances detailed below), hypokalemia (allowances detailed below), and acceptable blood counts as summarized above. A 2-week washout period was required from prior cetuximab; a 3-week washout period was required from any prior cytotoxic chemotherapy, targeted therapy, immunotherapy, or investigational agent. Significant lung disease, including pulmonary hypertension or interstitial pneumonia. Decreased serum albumin <30g / L (<3g / dL) Peripheral edema ≥ Grade 2 according to NCI-CTCAE 4.0 Significant electrolyte abnormalities prior to enrollment (note that patients may be supplemented to achieve acceptable electrolyte values): Hypomagnesemia < 1.2 mg / dL or 0.5 mmol / L Hypocalcemia <8.0mg / dL or 2.0mmol / L Hypokalemia < 3.0mmol / L ·Serious cardiovascular disease, including: New York Heart Association (NYHA) Class III or IV heart failure Myocardial infarction, severe angina, or unstable angina within 6 months prior to the first day of the study History of severe ventricular arrhythmias (i.e., ventricular tachycardia or ventricular fibrillation) Cardiac arrhythmias requiring rhythm medications. Note that beta-blockers, calcium channel blockers, and digoxin administered for rate control of supraventricular tachycardia, including atrial fibrillation and atrial flutter, are not classified as rhythm medications for study eligibility purposes. Major thrombotic or embolic events within 4 weeks prior to Study Day 1. Major thrombotic or embolic events included, but were not limited to, stroke or transient ischemic attack (TIA). Catheter-related thrombosis was not a basis for exclusion. Diagnosis of deep vein thrombosis or pulmonary embolism was permitted if made >4 weeks prior to Study Day 1 and the patient was asymptomatic and stable on anticoagulation. Any other medical condition (e.g. alcohol abuse) or psychiatric condition which, in the opinion of the investigator, would prevent the subject from participating in the study or would interfere with the interpretation of the study results. History of a second malignancy within 2 years prior to Study Day 1 (excluding resected and cured non-melanoma skin cancer, carcinoma in situ of breast or cervical cancer, superficial bladder cancer, resected or observed stage I differentiated thyroid cancer, or pT1a / pT1b prostate cancer with normal prostate-specific antigen (PSA) since resection involving <5% resected tissue, or cT1a / cT1b prostate cancer treated with brachytherapy or external beam radiation therapy with normal PSA since radiation). Major surgery within 6 weeks prior to Study Day 1 (subjects must be fully recovered from any prior surgery prior to Study Day 1). Active infection requiring systemic antibiotics or antifungals within 7 days prior to the first dose of study drug. Exception: Tetracycline family antibiotics (tetracycline, doxycycline, minocycline) administered for management of cetuximab-associated rash may be continued at the investigator's discretion. HIV-positive patients receiving combination antiretroviral therapy were excluded from the study because of possible drug interactions with the study drugs. Women must not be pregnant or breastfeeding because ficlatuzumab and / or cetuximab may be harmful to the fetus or infant. Pregnant women were excluded because ficlatuzumab and / or cetuximab may have teratogenic or abortifacient effects.

[0191] C. Randomization Randomization to ficlatuzumab versus the combination of ficlatuzumab and cetuximab was performed in the UACC Biostatistics Shared Resource. Patients were stratified by HPV status, a known prognostic factor in recurrent / metastatic HNSCC.

[0192] For stratification purposes, HPV-positive HNSCC was assessed by p16 status following standard of care at local site. To be classified as HPV-positive, patients had to meet the following criteria: 1) either oropharynx or unknown primary site; and 2) ≥70% of tumor cells were both p16+ by immunohistochemistry, showing diffuse nuclear and cytoplasmic staining with p16 antibody. For stratification purposes, the remainder of patients were classified as HPV-negative.

[0193] d. Treatment plan Ficlatuzumab was administered as an IV infusion. Ficlatuzumab was administered at a dose of 20 mg / kg IV every 2 weeks (+ / - 3 days) starting on the same day as the first dose of cetuximab. Ficlatuzumab was administered over 30-60 minutes. Protocol specific dose modifications were permitted. See Table 1 below for dose reduction levels. Cetuximab was administered first. Ficlatuzumab was administered 30-60 minutes after completion of the cetuximab infusion.

[0194] Cetuximab was administered as an IV infusion at 500 mg / m 2 IV doses were administered every 2 weeks (+ / - 3 days) starting on the same day as the first dose of ficlatuzumab. The first dose was administered over 120 minutes (+ / - 15 minutes) and subsequent doses were allowed to be infused over 60 minutes (+ / - 15 minutes). Protocol specific dose modifications were allowed. See Table 1 below for dose reduction levels. Cetuximab was administered at 500 mg / m 2 IV doses were administered every 2 weeks (+ / - 3 days) starting on the same day as the first dose of ficlatuzumab. The first dose was administered over 120 minutes (+ / - 15 minutes), and subsequent doses were allowed to be infused over 60 minutes (+ / - 15 minutes). Protocol-specific dose modifications were allowed. See Table 1 below for dose reduction levels.

[0195] In the absence of treatment delays due to adverse events, treatment was continued until disease progression or until one of the following criteria was met: - intercurrent illness that prevented further administration of treatment, Unacceptable adverse events, - Patients were selected to discontinue the study for any reason, - In the opinion of the investigator, a general or specific change in the patient's condition made further treatment unacceptable to the patient.

[0196] Patients were followed for survival every 3 months for 2 years from withdrawal from the study or until death, whichever occurred first. Patients who were withdrawn from the study because of intolerable adverse events were followed until resolution or stabilization of the adverse event.

[0197] e. Dose Delays and Modifications The following table summarizes the dose levels that are available for protocol specific de-escalations for ficlatuzumab and / or cetuximab (Table 1).

[0198] [Table 1]

[0199] During Phase I development, no severe (grade 3-4) myelosuppression was observed with ficlatuzumab monotherapy or in combination with an EGFR inhibitor, while dose modifications for neutropenia or thrombocytopenia, if observed, are identified in Table 2A. Because cetuximab does not cause myelosuppression, any neutropenia or thrombocytopenia observed did not affect the cetuximab dose.

[0200] [Table 2]

[0201] Adverse events observed and considered, at least possibly, related to study drug were managed according to guidelines for dose interruption, delay, or reduction.

[0202] If toxicity was clearly and solely attributable to ficlatuzumab, ficlatuzumab was withheld or reduced as described below in Table 2B. If toxicity was at least possibly related to both ficlatuzumab and cetuximab, both study drugs were modified as described below.

[0203] [Table 3A]

[0204] [Table 3B]

[0205] [Table 3C]

[0206] [Table 3D]

[0207] Subjects were permitted up to two dose reductions. Subjects at the lowest ficlatuzumab dose level (10 mg / kg) who experienced attributable grade 3 or 4 toxicity discontinued ficlatuzumab. However, subjects were allowed to resume treatment at 10 mg / kg after AEs resolved or improved to ≦grade 2 or baseline if, in the investigator's opinion, there was evidence of clinical benefit.

[0208] If any observed toxicity, potentially related to at least ficlatuzumab and / or cetuximab, prevented dosing during a scheduled study visit, the dose for that study visit was skipped and the next scheduled dose of study drug was administered. If two consecutive doses were missed as a result of ficlatuzumab-related toxicity, ficlatuzumab was permanently discontinued. However, subjects who missed two consecutive doses were allowed to resume treatment after AEs had resolved to the minimum specifications in Tables 2A-2B if, in the investigator's opinion, there was evidence of clinical benefit.

[0209] Cetuximab-related skin toxicity was graded according to the criteria outlined in Table 3 below. Per physician discretion, if a patient developed a rash ≥ grade 3, cetuximab treatment was adjusted according to Tables 2A-2B above. Patients with mild and moderate skin adverse events continued cetuximab without adjustment.

[0210] [Table 4]

[0211] Dry skin and skin rashes ranging from erythema to impetigo are quite common during cetuximab therapy. Biopsies of the papulopustular rash demonstrate histopathological suppurative inflammation rather than acne vulgaris. The initial rash is sterile, but superinfection can occur.

[0212] Patients who developed cutaneous AEs while receiving cetuximab were monitored for the development of inflammatory or infectious sequelae and initiated appropriate treatment for those conditions.

[0213] Management of reactions to cetuximab infusions was as described in Table 4.

[0214] [Table 5]

[0215] In the event of acute onset (grade ≥ 2) or worsening of pulmonary symptoms not believed to be related to the underlying cancer, both cetuximab and ficlatuzumab were interrupted and the symptoms were immediately investigated. Patients were not re-treated with either ficlatuzumab or cetuximab until the symptoms had resolved to grade 1. If interstitial lung disease was confirmed, both cetuximab and ficlatuzumab were permanently discontinued and patients were managed appropriately.

[0216] f. Response evaluation For the purposes of this study, patients' responses were reassessed every 8 weeks.

[0217] In this study, response and progression were assessed using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) (Eisenhauer, EA et al., Eur J Cancer (2009) 45:228-247). Changes in the maximum diameter of tumor lesions (unidimensional measurement) and, in the case of malignant lymph nodes, changes in the minimum diameter were used.

[0218] Malignant Disease Evaluation To assess objective response, it was necessary to estimate the total tumor burden at baseline, to which subsequent measurements were compared. Measurable disease was defined by the presence of at least one measurable lesion.

[0219] All measurements were recorded in metric notation using a ruler or calipers. The same assessment methods and techniques were used to characterize each identified lesion at baseline and during follow-up. All baseline assessments were performed as close as possible to the start of treatment and no more than 4 weeks prior to enrollment.

[0220] At baseline, primary tumors and pathological cervical lymph nodes were characterized as either measurable or non-measurable.

[0221] A measurable primary tumor is a lesion that can be precisely measured in at least one dimension (longest recorded diameter) to ≧20 mm (2.0 cm) by conventional techniques or ≧10 mm (1.0 cm) by spiral CT scan.

[0222] Cervical lymph nodes were considered pathological and measurable if their short axis was ≥15 mm. Cervical lymph nodes were considered pathological but not measurable if their short axis was ≥10 mm but <15 mm. Cervical lymph nodes were considered nonpathological and not measurable if their short axis was <10 mm.

[0223] All other lesions, including small lesions [longest diameter <20 mm (2.0 cm) by conventional techniques or <10 mm (1.0 cm) by spiral CT scan], were truly nonmeasurable lesions.

[0224] Lesions considered truly non-measurable include the following: bone lesions, leptomeningeal disease, ascites, pleural / pericardial effusion, inflammatory breast disease, lymphangitis cutis / pulmonis, abdominal masses not identified and tracked by imaging techniques, and cystic lesions.

[0225] All measurable lesions, up to a maximum of two per organ and up to a maximum of five total, representing all involved organs, were identified as target lesions, recorded and measured at baseline. Target lesions were selected based on their size (lesions with the longest diameter), representative of all involved organs, and suitable for reproducible repeated measurements. If the largest lesion was not suitable for repeated measurements, the next largest lesion that was reproducibly measurable was selected in that situation. The sum of the diameters of all target lesions (longest diameter for non-nodal lesions, short axis for nodal lesions) was calculated and reported as the baseline sum of diameters. When lymph nodes were included in the sum, only the short axis was included in the sum. The baseline sum of diameters was used as a reference to further characterize any objective tumor regression in the measurable dimensions of disease.

[0226] The sum of the longest diameters of the primary tumor and the sum of the short-axis diameters of the target pathological lymph nodes were calculated at baseline and reported as the baseline sum diameters. All other lesions (or disease sites), including any measurable lesions other than the five target lesions, were identified as non-target lesions and reported at baseline. Measurement of those lesions was not required, but the presence, absence, or in rare cases, frank progression of each was noted throughout follow-up.

[0227] Response Criteria With regard to the evaluation of target lesions, a complete response (CR) was the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to have a reduction in short axis to <10 mm. A partial response (PR) was a decrease of at least 30% in the sum of target lesion diameters (longest diameter of non-nodal lesions; short axis diameter of target lymph nodes) based on the baseline sum of diameters. Progressive disease (PD) was an increase of at least 20% in the sum of target lesion diameters (longest diameter of non-nodal lesions; short axis diameter of target lymph nodes) based on the smallest sum of longest diameters recorded since the baseline sum of diameters measurement. The sum had to show an absolute increase of at least 5 mm in addition to a relative increase of 20%. The appearance of one or more new lesions was also considered as progression. Stable disease (SD) was neither a sufficient reduction to qualify for PR nor a sufficient increase to qualify for PD based on the smallest sum of longest diameters during the study.

[0228] With regard to the assessment of non-target lesions (all other lesions or disease sites should have been noted, but not required), a complete response (CR) was the disappearance of all non-target lesions. A partial response / stable disease (SD) was the persistence of one or more non-target lesions. Progressive disease (PD) was the appearance of one or more new lesions and / or a clear worsening of existing non-target lesions. Clear worsening did not usually go beyond the target lesion status. It should be representative of the overall disease change, not an increase in a single lesion. Clear worsening of only "non-target" lesions was the exception, but in such circumstances the opinion of the treating physician took precedence, and the progression status was subsequently confirmed by the review committee (or principal investigator).

[0229] Patients with a global deterioration in health status necessitating discontinuation of treatment without subsequent objective evidence of disease progression were classified as having symptomatic deterioration.

[0230] The best overall response was the best response recorded from enrollment to disease progression / recurrence based on the smallest measurement recorded since enrollment for progressive disease. Table 5 below presents the overall response for all possible combinations of tumor response, with or without new lesions, in target and non-target lesions.

[0231] To be assigned to stable status, measurements must meet the stability criteria at least once after study enrollment, with a minimum interval of 8 weeks.

[0232] [Table 6]

[0233] First recorded response is the time between initiation of therapy and the first recorded PR or CR.

[0234] To be assigned a complete or partial response status, a change in tumor measurement had to be confirmed by a repeat assessment performed at least 4 weeks after the criteria for response were first met.

[0235] Duration of overall response was measured from when the measurement criteria for complete response or partial response were met (whichever was first recorded) to the first date of objectively documented recurrent or progressive disease, based on the smallest measurement recorded since the start of treatment.

[0236] The overall duration of complete response was the time measured from when the measurement criteria for complete response were met to the first date of objectively documented recurrent disease.

[0237] The stable disease period was measured from enrollment until criteria for disease progression were met based on the smallest measurements recorded since enrollment. To be assigned to stable disease, measurements had to meet the stable disease criteria at least once after study enrollment, with a minimum interval of 6 weeks.

[0238] Survival was measured from the date of entry into the study.

[0239] Time to progression and progression-free survival were measured from the date of study entry until the appearance of new metastatic lesions or objective tumor progression.

[0240] Progression-free survival (PFS) was calculated from the start of treatment until disease progression or death from any cause.

[0241] g. Drug information Ficlatuzumab Concentrate for Injection 20 mg / mL was formulated in 10 mM histidine buffer pH 5.8. The formulation also contains 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product was sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials. An overage in the vial was provided to ensure that the 4.0 mL label volume was retrievable. The product was a clear to slightly opalescent, colorless to slightly yellow solution.

[0242] Ficlatuzumab concentrate for injection was administered by IV infusion as a mixture with normal saline solution. The mixed solution in the IV bag was connected to an infusion set containing a 0.22 μm low protein binding in-line filter. The IV bag and infusion set containing the in-line filter were shown to be compatible with the mixture. The filtered mixed solution was clear to slightly opalescent.

[0243] Ficlatuzumab was stored in a secure place under refrigerated conditions (2°C to 8°C).

[0244] Cetuximab is an anti-EGFR receptor humanized chimeric monoclonal antibody. Cetuximab was expressed in SP2 / 0 myeloma cell line, grown in large-scale cell culture bioreactors, and purified to a high level of purity using several purification steps, including protein A chromatography, ion exchange chromatography, low pH treatment, and nanofiltration. Cetuximab is not known to be a vesicant.

[0245] Preparation and Administration: Cetuximab was not administered as an IV push or bolus. Cetuximab was administered using a low protein binding 0.22 micrometer in-line filter.

[0246] Cetuximab was supplied in a 50-mL single-use vial containing 100 mg of cetuximab at a concentration of 2 mg / mL in phosphate-buffered saline. The solution was clear and colorless and may contain small amounts of easily visible amorphous white cetuximab particles.

[0247] Cetuximab was administered via an infusion pump or a syringe pump, where the cetuximab was piggybacked onto the patient's infusion line.

[0248] Following cetuximab infusion, a 1-hour observation period was recommended.

[0249] 2.Results As shown in Figures 1 and 2, a total of 60 patients were randomized, and a total of 58 patients started study treatment from January 2018 to December 2020. The baseline characteristics of the study population were matched across the two treatment groups (Figure 3). By design, all patients were cetuximab resistant, and the median time since prior cetuximab exposure was 2.7 months and 3.6 months for the ficlatuzumab and combination groups, respectively. Fifty-four of the 60 patients (90%) progressed on anti-PD1 mAb, and 43 patients (72%) were platinum resistant. Ten of the 60 patients (17%) were racial or ethnic minorities, which are underrepresented in clinical studies.

[0250] Ficlatuzumab monotherapy group As shown in Figures 6A and 6B, the ficlatuzumab monotherapy group was stopped for futility after 26 evaluable subjects achieved a median progression-free survival (mPFS) of 1.8 months (90% CI lower limit: 1.7 months), a median OS of 4.9 months (90% CI lower limit, 3.3 months), and an overall response rate (ORR) of 1 / 26 (4%), with one response being a partial response in HPV-negative controls.

[0251] Ficlatuzumab and cetuximab combination group The ficlatuzumab and cetuximab combination arm completed the primary endpoint with accrual of 32 evaluable subjects. Subjects in the ficlatuzumab and cetuximab combination arm achieved a mPFS of 3.6 months (lower limit of 90% CI, 2.3 months; p=0.04; Figure 5A), fulfilling the protocol-specific criteria for a phase III trial. Median OS was 7.3 months (lower limit of 90% CI, 4.8 months; Figure 5B). ORR was 6 / 32 (19%), including 2 complete responses (CR) and 4 partial responses (PR). One patient in CR died of unrelated cardiovascular disease and remained in CR. The second patient remained in CR 46 months after the start of protocol treatment and was on ficlatuzumab alone from month 18 onwards due to a recurrent, severe acneiform rash despite a reduction in the dose of cetuximab. As shown by the PFS Kaplan-Meier curves in Figure 5A, all patients who received ficlatuzumab progressed by approximately 9 months, whereas some ficlatuzumab / cetuximab subjects remained progression-free beyond 15 months. A similar trend was observed in Figure 5B comparing the control and treatment groups. The data suggest that subjects receiving the combination treatment may have a greater likelihood of a favorable outcome.

[0252] It is noteworthy that all objective responses occurred in patients with HPV-negative disease. Because of the unexpectedly high response rate in all refractory HPV-negative disease, a post-hoc analysis was performed in the HPV stratified subgroups for the combination arm. As shown in Figure 6A, the ORR in HPV-negative patients versus HPV-positive patients was 0 / 16 (0%) vs. 6 / 16 (38%), p=0.02. Median PFS was 2.3 vs. 4.1 months, p=0.03 (Figure 6B). A sensitivity analysis was performed on the ORR in HPV-negative patients excluding those who had never received platinum due to medical ineligibility; the ORR was 5 of 13 (38%).

[0253] Notably, the ORR in HPV-positive subjects was 0% as none of the HPV-positive subjects were responders, whereas the ORR in HPV-negative subjects was 38%, with 2 complete responses and 4 partial responses recorded among the 16 negative patients (p=0.02). The mPFS of HPV-positive subjects was 2.3 months compared to 4.1 months in HPV-negative subjects, with superior ORR (p=0.02) and mPFS (p=0.03). Furthermore, as shown by the Kaplan-Meier curves in Figure 6B, all HPV-positive subjects progressed by approximately 6 months, whereas at approximately 18 months, some subjects remained progression-free. The longer survival of HPV-negative HNSCC subjects is a surprising result, considering the extremely poor prognosis of these patients based on the currently available standard of care.

[0254] These results are significant because treatment of HNSCC with cetuximab has provided only modest benefit in these cancers, with an ORR of 10-13%. Thus, among other things, the present disclosure provides compositions and treatment regimens for subjects with HPV-negative HNSCC that provide improved clinical outcomes compared to current standard of care, such as platinum therapy or immunotherapy (e.g., immune checkpoint inhibitors such as pembrolizumab) with cetuximab.

[0255] The data clearly show that HPV-negative subjects experience superior outcomes compared to HPV-positive subjects, supporting the significant therapeutic benefit of this combination therapy in HPV-negative subjects. This was surprising, since HPV-positive patients generally fare better than HPV-negative patients with conventional treatments for HNSCC, and HPV-positive status is a positive prognostic indicator. Therefore, the discovery that HPV-negative status may be a positive prognostic indicator for treatment with cetuximab and ficlatuzumab in recurrent / metastatic HNSCC, while HPV-positive status may be a negative prognostic indicator, is entirely surprising and unexpected.

[0256] Thus, the data suggest that subjects with HPV-negative recurrent or metastatic HNSCC may benefit greatly from treatment with cetuximab and ficlatuzumab compared with cetuximab alone as the standard of care for second-line or back-line therapy in subjects with immune checkpoint-resistant and / or platinum-resistant HNSCC.

[0257] toxicity Safety data, including treatment-emergent AEs attributable to ficlatuzumab and / or cetuximab, are summarized in Figure 4. In the monotherapy group, the most common AEs were hypoalbuminemia (30%) and edema (27%), toxicity classes expected for HGF / cMet inhibitors. In the combination group, the most common toxicities were acneiform rash (63%), hypoalbuminemia (31%), and edema (22%), toxicity classes for EGFR inhibitors. Three cases of pneumonitis, a rare but known toxicity class for HGF / cMet inhibitors, were observed, two in the monotherapy group (including one fatal AE) and one in the combination group.

[0258] Figure 4 presents a detailed breakdown of the types of toxicities observed, categorised by grade 1–2 and ≥ grade 3. In the ficlatuzumab group, grade 1–2 edema, fatigue, acneiform rash, skin infection, and hypoalbuminemia were observed, along with higher grade edema, maculopapular rash, and pneumonitis. In the combination group, observed grades 1–2 included edema, weight loss, various skin toxicities, anorexia, mucositis, hypoalbuminemia, and pneumonitis, with some grade ≥ 3 edema, fatigue, and skin and gastrointestinal toxicities. The data indicate that combination therapy with ficlatuzumab and cetuximab was well tolerated, with toxicity classes expected from an HGF / c-MET inhibitor, including the common adverse events edema and hypoalbuminemia, and the rare adverse event pneumonitis.

[0259] Example 2 A Phase III Study Evaluating Cetuximab and Ficlatuzumab in Subjects With Recurrent or Metastatic HNSCC Who Are HPV Negative A Phase III study will be conducted to evaluate the treatment of subjects with recurrent or metastatic HNSCC who are HPV negative. Subjects with recurrent or metastatic HNSCC who are determined to be HPV negative and who are platinum resistant or platinum ineligible and / or immune checkpoint inhibitor resistant or immune checkpoint inhibitor ineligible will be included in two study arms: cetuximab at 500 mg / m 2 and a control group administered 500 mg / m every 2 weeks at a dose of 2 Patients will be randomized to a treatment arm in which cetuximab at 0.05 mg / kg is administered iv concomitantly with ficlatuzumab at 20 mg / kg every 2 weeks.

[0260] Subjects remain on the study until discontinuation for any reason, including progression, death, or experiencing unacceptable toxicity.

[0261] Based in part on the results from the Phase II study in Example 1, the results are expected to show that both median progression-free survival and overall survival are statistically significantly greater in the treatment group than in the control group. The results are also expected to show that subjects with HNSCC who are HPV-negative and platinum-resistant or platinum-ineligible and / or immune checkpoint inhibitor-resistant or immune checkpoint inhibitor-ineligible experience greater clinical benefit from treatment with cetuximab and ficlatuzumab than with cetuximab alone. Safety data are expected to show that the combination of ficlatuzumab and cetuximab is well tolerated with acceptable toxicity classes.

[0262] [Table 7A]

[0263] [Table 7B]

[0264] [Table 7C]

[0265] [Table 7D]

[0266] [Table 7E]

[0267] [Table 7F]

[0268] [Table 7G]

Claims

1. 1. A method of treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in a subject, comprising: Identifying a subject with recurrent or metastatic HNSCC who is human papillomavirus (HPV) negative; and administering to the subject an effective amount of cetuximab together with an effective amount of ficlatuzumab to treat HNSCC that is HPV negative. A method comprising:

2. 10. The method of claim 1, wherein the subject is not treated if the subject has recurrent or metastatic HNSCC that is HPV positive.

3. The method of claim 1 or 2, wherein the HPV status of the HNSCC is determined by p16 immunohistochemistry.

4. 4. The method of claim 1 or 3, wherein the HNSCC is classified as p16 negative, or, if the HNSCC is a primary oral, laryngeal, or hypopharyngeal HNSCC, the HNSCC is HPV negative.

5. 4. The method of claim 2 or 3, wherein if the HNSCC is classified as p16 positive, then the HNSCC is HPV positive.

6. 6. The method of claim 1, wherein the HPV status of the HNSCC is determined by tumor DNA analysis, and the HNSCC is HPV negative based on the absence of HPV DNA in the tumor.

7. 7. The method of any one of claims 1 to 6, wherein the HNSCC in the subject has not been previously treated with cetuximab.

8. 8. The method of any one of claims 1 to 7, wherein the HNSCC in the subject has been previously treated with PD-1 or PD-L1 immunotherapy.

9. 9. The method of any one of claims 1 to 8, wherein the HNSCC is resistant to PD-1 or PD-L1 immunotherapy.

10. 10. The method of claim 8 or 9, wherein the immunotherapy is selected from pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, tremelimumab, or tisotumab.

11. 11. The method of any one of claims 8 to 10, wherein the immunotherapy is pembrolizumab.

12. 12. The method of any one of claims 1 to 11, wherein the HNSCC in the subject has been previously treated with platinum chemotherapy.

13. 13. The method of any one of claims 1 to 12, wherein the HNSCC is platinum-resistant.

14. 14. The method according to claim 12 or 13, wherein the platinum chemotherapy is carboplatin, oxaliplatin, cisplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin or satraplatin.

15. 15. The method of any one of claims 12 to 14, wherein the platinum chemotherapy is cisplatin or carboplatin.

16. 12. The method of any one of claims 1 to 11, wherein the subject is unsuitable for platinum chemotherapy.

17. 17. The method of any one of claims 1 to 16, wherein the HNSCC in the subject has been previously treated with 5-fluorouracil or other antimetabolite chemotherapy.

18. 18. The method of any one of claims 1 to 17, wherein the HNSCC has been previously treated with pembrolizumab with or without platinum and with or without 5-fluorouracil as first-line therapy.

19. 19. The method of any one of claims 1 to 18, wherein treating HNSCC with cetuximab and ficlatuzumab is a second line therapy.

20. 20. The method of any one of claims 1 to 19, wherein the HNSCC originates from a primary site in the oral cavity, pharynx or larynx.

21. 21. The method of any one of claims 1 to 20, wherein the HNSCC is hypopharyngeal cancer, laryngeal cancer, lip or oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus or nasal cavity cancer, or salivary gland cancer.

22. 22. The method of any one of claims 1 to 21, wherein the dose of ficlatuzumab is from 10 mg / kg to 100 mg / kg.

23. 23. The method of any one of claims 1 to 22, wherein the dose of ficlatuzumab is between 10 mg / kg and 50 mg / kg.

24. 24. The method of any one of claims 1 to 23, wherein the dose of ficlatuzumab is 10 mg / kg.

25. 24. The method of any one of claims 1 to 23, wherein the dose of ficlatuzumab is 15 mg / kg.

26. 24. The method of any one of claims 1 to 23, wherein the dose of ficlatuzumab is 20 mg / kg.

27. 27. The method of any one of claims 1 to 26, wherein a dose of ficlatuzumab is administered by intravenous administration every two weeks.

28. 27. The method of any one of claims 1 to 26, wherein a dose of ficlatuzumab is administered by intravenous administration every 2 weeks + / - 3 days.

29. The dose of cetuximab was 250 to 700 mg / m 2 29. The method of any one of claims 1 to 28, wherein

30. The dose of cetuximab is 300 to 500 mg / m 2 30. The method of any one of claims 1 to 29, wherein

31. The dose of cetuximab was 500 mg / m 2 31. The method of any one of claims 1 to 30, wherein

32. The dose of cetuximab was 400 mg / m 2 32. The method of any one of claims 1 to 31, wherein

33. The dose of cetuximab was 300 mg / m 2 33. The method of any one of claims 1 to 32, wherein

34. 34. The method of any one of claims 1 to 33, wherein the dose of cetuximab is administered by intravenous administration every two weeks.

35. 34. The method of any one of claims 1 to 33, wherein a dose of cetuximab is administered by intravenous administration every 2 weeks + / - 3 days.

36. 36. The method of any one of claims 1 to 35, wherein the dose of cetuximab and the dose of ficlatuzumab are administered on the same day.

37. 37. The method of any one of claims 1 to 36, wherein the dose of cetuximab and the dose of ficlatuzumab are administered simultaneously or sequentially by intravenous administration.

38. 38. The method of any one of claims 1 to 37, wherein cetuximab and ficlatuzumab are administered to the subject until progression, occurrence or new metastasis of the HNSCC, or until the patient experiences unacceptable toxicity.

39. 1. A method for identifying a subject having head and neck squamous cell carcinoma (HNSCC) suitable for combination therapy with ficlatuzumab and cetuximab, comprising assessing whether the HNSCC is human papillomavirus (HPV) negative or HPV positive, and if the HNSCC is human papillomavirus (HPV) negative, the subject is identified as suitable for combination therapy.

40. 40. The method of claim 39, wherein if the patient is HPV positive, the patient is not suitable for combination therapy.

41. 40. The method of claim 39, wherein the subject is identified as suitable for combination therapy if the HNSCC is platinum resistant or the subject is unsuitable for platinum chemotherapy.

42. 42. The method of any one of claims 39 to 41, wherein if the HNSCC is not responsive to immunotherapy with a PD-1 or PD-L1 inhibitor, the subject is identified as suitable for combination therapy.

43. 43. The method of any one of claims 39-42, wherein the subject is identified as suitable for combination therapy if the HNSCC is platinum resistant and not responsive to immunotherapy with a PD-1 or PD-L1 inhibitor.

44. 44. The method of claim 42 or 43, wherein the subject is identified as suitable for combination therapy when the immunotherapy is pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, durvalumab, ipilimumab, tremelimumab or tisotumab.

45. 45. The method of any one of claims 42 to 44, wherein when the immunotherapy is pembrolizumab, the subject is identified as suitable for combination therapy.

46. 46. ​​The method of any one of claims 41 to 45, wherein the subject is identified as suitable for combination therapy when the platinum is carboplatin or cisplatin.

47. 47. The method of any one of claims 39 to 46, wherein if the HNSCC is recurrent or metastatic, the subject is identified as suitable for combination therapy.

48. 48. The method of any one of claims 39 to 47, further comprising administering the combination therapy to the subject if the subject is identified as suitable for the combination therapy.

49. 49. The method of any one of claims 39 to 48, wherein the HPV status of the HNSCC is determined by p16 immunohistochemistry.

50. 50. The method of any one of claims 39 to 49, wherein the HNSCC is classified as p16 negative and / or, if the HNSCC is an HNSCC of primary site in the oral cavity, larynx, or hypopharynx, the HNSCC is HPV negative.

51. 50. The method of any one of claims 39 to 49, if the HNSCC is classified as p16 positive, then the HNSCC is HPV positive.

52. 52. The method of any one of claims 39 to 51, wherein the HPV status of the HNSCC is determined by tumor DNA analysis, and the HNSCC is HPV negative based on the absence of HPV DNA in the tumor, or HPV positive based on the presence of HPV DNA in the tumor.

53. 53. The method of any one of claims 39 to 52, wherein the HNSCC originates from a primary site in the oral cavity, pharynx or larynx.

54. 54. The method of any one of claims 39 to 53, wherein the combination therapy is a second line therapy.

55. 55. The method of any one of claims 39 to 54, wherein the combination therapy comprises administering a dose of ficlatuzumab that is between 10 mg / kg and 100 mg / kg.

56. 56. The method of any one of claims 39 to 55, wherein the combination therapy comprises administering a dose of ficlatuzumab that is between 10 mg / kg and 50 mg / kg.

57. 57. The method of any one of claims 39 to 56, wherein the combination therapy comprises administering a dose of ficlatuzumab that is 20 mg / kg, 15 mg / kg, or 10 mg / kg.

58. 58. The method of any one of claims 39-57, wherein the combination therapy comprises administering doses of ficlatuzumab and cetuximab intravenously every two weeks.

59. 58. The method of any one of claims 39-57, wherein the combination therapy comprises administering doses of ficlatuzumab and cetuximab intravenously every 2 weeks + / - 3 days.

60. Combination therapy is 250 to 700 mg / m 2 60. The method of any one of claims 39-59, comprising administering a dose of cetuximab which is

61. Combination therapy is 300 to 500 mg / m 2 61. The method of any one of claims 39 to 60, comprising administering a dose of cetuximab which is

62. Combination therapy is 500 mg / m 2 62. The method of any one of claims 39-61, comprising administering a dose of cetuximab which is

63. 63. The method of any one of claims 39 to 62, wherein the combination therapy comprises administering a dose of cetuximab and a dose of ficlatuzumab on the same day, simultaneously or sequentially, by intravenous administration.

64. 64. The method of any one of claims 39 to 63, wherein the HNSCC is hypopharyngeal cancer, laryngeal cancer, lip or oral cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, paranasal sinus or nasal cavity cancer, or salivary gland cancer.

65. A method for treating cancer in a subject in need of treatment, comprising the step of administering to the subject therapeutically effective amounts of an anti-HGF antibody or antigen-binding fragment thereof and an anti-EGFR antibody or antigen-binding fragment thereof.

66. 66. The method of claim 65, wherein the cancer is head and neck squamous cell carcinoma (HNSCC).

67. 67. The method of claim 66, wherein the HNSCC is recurrent and / or metastatic.

68. 68. The method of claim 66 or 67, wherein the HNSCC is human papillomavirus (HPV) negative.

69. The anti-HGF antibody or antigen-binding fragment thereof, (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:1, a CDRH2 comprising the amino acid sequence of SEQ ID NO:2, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:3; and (ii) an immunoglobulin light chain variable region comprising CDRL1 comprising the amino acid sequence of SEQ ID NO:4, CDRL2 comprising the amino acid sequence of SEQ ID NO:5, and CDRL3 comprising the amino acid sequence of SEQ ID NO:6; 69. The method of any one of claims 65 to 68, comprising:

70. The method of any one of claims 65 to 69, wherein the anti-HGF antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain variable region comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 7; and (ii) an immunoglobulin light chain variable region comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO:

8.

71. The method of claim 69, wherein the anti-HGF antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7; and (ii) an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:

8.

72. The method of any one of claims 65 to 71, wherein the anti-HGF antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 17; and (ii) an immunoglobulin light chain comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO:

18.

73. The method of claim 72, wherein the anti-HGF antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 17; and (ii) an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:

18.

74. The method of any one of claims 65 to 73, wherein the anti-HGF antibody or antigen-binding fragment thereof is or is derived from a chimeric antibody, a human antibody or a humanized antibody.

75. The method of any one of claims 65 to 74, wherein the anti-HGF antibody or antigen-binding fragment thereof is selected from the group consisting of Fab, Fv, scFv, Fab', and (Fab')2.

76. 76. The method of any one of claims 65 to 75, wherein the anti-HGF antibody is selected from the group consisting of rilotumumab, ficlatuzumab, and combinations thereof.

77. The method of claim 76, wherein the anti-HGF antibody is ficlatuzumab.

78. The anti-EGFR antibody or antigen-binding fragment thereof, (i) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:9, a CDRH2 comprising the amino acid sequence of SEQ ID NO:10, and a CDRH3 comprising the amino acid sequence of SEQ ID NO:11; and (ii) an immunoglobulin light chain variable region comprising CDRL1 comprising the amino acid sequence of SEQ ID NO: 12, CDRL2 comprising the amino acid sequence of SEQ ID NO: 13, and CDRL3 comprising the amino acid sequence of SEQ ID NO: 14; 78. The method of any one of claims 65 to 77, comprising:

79. 79. The method of any one of claims 65 to 78, wherein the anti-EGFR antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain variable region comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 15; and (ii) an immunoglobulin light chain variable region comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO:

16.

80. 80. The method of claim 79, wherein the anti-EGFR antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15; and (ii) an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:

16.

81. 81. The method of any one of claims 65 to 80, wherein the anti-EGFR antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 19; and (ii) an immunoglobulin light chain comprising an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO:

20.

82. The method of claim 81, wherein the anti-EGFR antibody or antigen-binding fragment thereof comprises: (i) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO: 19; and (ii) an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:

20.

83. 83. The method of any one of claims 65 to 82, wherein the anti-EGFR antibody or antigen-binding fragment thereof is or is derived from a chimeric, human or humanized antibody.

84. The method of any one of claims 65 to 83, wherein the anti-EGFR antibody or antigen-binding fragment thereof is selected from the group consisting of Fab, Fv, scFv, Fab', and (Fab')2.

85. 85. The method of any one of claims 65 to 84, wherein the anti-EGFR antibody is selected from the group consisting of cetuximab, futuximab, imgatuzumab, matuzumab, necitumumab, nimotuzumab, panitumumab, amivantamab, zalutumumab, and combinations thereof.

86. 86. The method of any one of claims 65 to 85, wherein the anti-EGFR antibody is cetuximab.

87. The method of any one of claims 65 to 86, wherein the anti-HGF antibody or antigen-binding fragment thereof and the anti-EGFR antibody or antigen-binding fragment thereof are administered simultaneously or sequentially for at least one cycle of treatment.

88. 88. The method of any one of claims 65 to 87, wherein the anti-HGF antibody or antigen-binding fragment thereof is administered after the anti-EGFR antibody or antigen-binding fragment thereof for at least one cycle of treatment.

89. The method of any one of claims 65 to 88, wherein the anti-HGF antibody or antigen-binding fragment thereof and the anti-EGFR antibody or antigen-binding fragment thereof are each administered about once a week, about once every two weeks, about once every three weeks, or about once every four weeks.

90. The method of claim 89, wherein the anti-HGF antibody or antigen-binding fragment thereof and the anti-EGFR antibody or antigen-binding fragment thereof are each administered about every two weeks.

91. The method of any one of claims 65 to 90, wherein the anti-HGF antibody or antigen-binding fragment thereof is administered at about 2 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, or about 25 mg / kg.

92. The method of claim 91, wherein the anti-HGF antibody or antigen-binding fragment thereof is administered at about 20 mg / kg.

93. The anti-EGFR antibody or antigen-binding fragment thereof is about 200 mg / m 2 , about 250mg / m 2 , about 300mg / m 2 , about 400mg / m 2 , about 500mg / m 2 , about 600mg / m 2 , about 700mg / m 2 , or about 800 mg / m 2 93. The method of any one of claims 65 to 92, wherein the administration is

94. The anti-EGFR antibody or antigen-binding fragment thereof is about 500 mg / m 294. The method of claim 93, wherein the

95. The method of any one of claims 85 to 94, wherein the anti-HGF antibody or antigen-binding fragment thereof and the anti-EGFR antibody or antigen-binding fragment thereof are administered by intravenous infusion.

96. (i) 20 mg / kg of ficlatuzumab, and (ii) 500 mg / m 2 96. The method of any one of claims 65 to 95, comprising administering to the subject a dose of cetuximab every two weeks.

97. 87. A composition comprising an anti-HGF antibody or antigen-binding fragment thereof as defined in any one of claims 69 to 77, and an anti-EGFR antibody or antigen-binding fragment thereof as defined in any one of claims 78 to 86.

98. 98. The composition of claim 97, further comprising a pharma- ceutically acceptable carrier.

Citation Information

Patent Citations

  • PSGL-1 antagonists and uses thereof

    WO2018132476A1